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SUMMARY 
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SUMMARY 
The organization of the genome in a eukaryotic cell is quite complex and dynamic.  
Chromatin is compacted at various levels inside the cell nucleus and these correlate 
with specific epigenetic modifications like DNA and histone modifications and the 
presence of proteins that recognize these modifications. All these processes can affect 
DNA accessibility and, consequently, the establishment and maintenance of tissue 
specific gene expression patterns. 
During cellular differentiation, lineage specific genes become transcriptionally activated 
and, concomitantly, the remaining of the genome is silenced and stably kept in a 
heterochromatic state. Two major families of factors recognize the typical 
heterochromatic modifications: the MBD family consisting of MBD1, MBD2, MBD3, 
MBD4 and MeCP2; and the HP1 family comprising HP1α, HP1β and HP1γ. 
I investigated initially whether there is potential cross talk between these two families of 
epigenetic factors (MeCP2 and HP1) and how they work in synergy and affect each 
other during differentiation. I found that, in contrast to MeCP2, the level of expression of 
the three HP1s remained constant during myogenic differentiation, though HP1γ 
relocalized to heterochromatin. The latter was correlated with the presence of MeCP2. 
In agreement with this, I could show that MeCP2 directly interacted via its N terminal 
domain with the chromoshadow domain of HP1.  
Our group has recently shown that MeCP2 level increased dramatically during 
differentiation, and that MeCP2, via its methyl-cytosine binding domain, induced 
heterochromatin clustering in vivo. Hence, I next tested the role of MeCP2 in large-scale 
heterochromatin organization by analyzing whether this MeCP2 function is disrupted in 
disease. In 1999, MECP2 gene was found to be mutated in a neurological disease 
called Rett syndrome. Little is known about how MeCP2 causes Rett syndrome. Most 
studies so far have focused on finding MeCP2 target genes. I have concentrated my 
efforts on testing whether MeCP2 Rett mutations have an effect on its ability to bind and 
reorganize chromatin. I found that several methyl-cytosine binding domain mutations 
significantly disrupted MeCP2’s ability either to bind or to cluster heterochromatin. 
These mutations segregated onto two distinct surfaces of the methyl-cytosine binding 
domain. These data assigns now novel functions to this domain, which is the most 
frequently mutated in Rett patients. 
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From this work, I conclude that MeCP2 plays an important function in regulating 
chromatin organization, and that disrupting this ability of MeCP2 may lead to disease
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ZUSAMMENFASSUNG 
Die Organisation des Genoms in einer eukaryotischen Zelle ist komplex und dynamisch. 
Chromatin wird auf mehreren Ebenen im Inneren des Zellkerns kondensiert, und diese 
Ebenen korrelieren mit den spezifischen epigenetischen Modifikationen wie DNA- und 
Histonmodifikationen sowie mit dem Vorhandenseins der Proteine, die diese 
Modifikationen erkennen. All diese Prozesse können die Verfügbarkeit der DNA und 
infolgedessen die Etablierung und Erhaltung gewebsspezifischer 
Genexpressionsmuster beeinflussen. 
Während der Zelldifferenzierung werden linienspezifische Gene durch Transkription 
aktiviert. Gleichzeitig wird das restliche Genom vorübergehend inaktiviert und stabil in 
einem heterochromatischen Stadium gehalten. Die Faktoren, die typische 
Heterochromatin-Modifikationen erkennen, werden in zwei Familien eingeteilt: Die 
MBD-Familie besteht aus MBD1, MBD2, MBD3, MBD4 und MeCP2; die HP1-Familie 
beinhaltet HP1α, HP1β und HP1γ. 
Anfänglich habe ich untersucht, ob es zwischen den zwei Familien epigenetischer 
Faktoren (MeCP2 und HP1) möglicherweise zu Interdependenzen kommt, wie sie 
zusammenwirken und sich während der Differenzierung gegenseitig beeinflussen. Wir 
fanden heraus, dass im Gegensatz zu MeCP2 die Expression der drei HP1s während 
der myogenen Differenzierung konstant blieb. Allerdings konnten wir eine Umverteilung 
von HP1γ zum Heterochromatin beobachten, die mit dem Vorhandensein von MeCP2 
korreliert. Damit übereinstimmend konnten wir zeigen, dass MeCP2 über seine 
terminale N-Domäne direkt mit der Chromoshadow-Domäne von HP1 interagiert. 
Unsere Arbeitsgruppe hat vor kurzem gezeigt, dass der MeCP2-Spiegel während der 
Differenzierung dramatisch ansteigt und MeCP2 über seine Methyl-Cytosin-bindende 
Domäne in vivo die Heterochromatin-Clusterbildung induziert. Demzufolge habe ich als 
nächstes die Rolle von MeCP2 in der übergeordneten Heterochromatin-Organisation 
untersucht und getestet, ob diese Funktion von MeCP2 bei einer Krankheit gestört ist. 
Seit 1999 ist bekannt, dass das MeCP2-Gen beim  Rett-Syndrom, einer neurologischen 
Erkrankung, mutiert ist. Es ist wenig darüber bekannt, wie MeCP2 das Rett-Syndrom 
auslöst. Die meisten Untersuchungen haben sich darauf konzentriert, MeCP2-Zielgene 
zu finden. Wir wollten herausfinden, ob Rett-MeCP2-Mutationen sich auf die Fähigkeit 
zur Bindung und Reorganisation von Chromatin auswirken. Es zeigte sich, dass 
mehrere Mutationen der Methyl-Cytosin-bindenden Domäne die Fähigkeit von MeCP2
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zur Bindung oder Clusterbildung von Heterochromatin stören. Diese Mutationen zeigten 
sich auf zwei genau umschriebenen Oberflächen der Methyl-Cytosin-bindenden 
Domäne. Die gewonnenen Daten weisen dieser Domäne, die bei Rett-Patienten am 
häufigsten mutiert, neue Funktionen zu. Wir schließen daraus, dass MeCP2 eine 
wichtige Rolle bei der Regulation der Chromatinorganisation spielt, und dass die 
Störung dieser Funktion von MeCP2 zu einer Erkrankung führen kann. 
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1. INTRODUCTION 
The expression and stability of the genome within the eukaryotic nucleus is controlled 
by chromatin organization. Misregulation of chromatin structure can lead to incorrect 
gene activation or improper gene silencing. In the past years, a lot of effort has 
concentrated in the identification of factors that contribute to the organization of 
chromatin within the cell nucleus. These studies have provided insight into many 
aspects of chromatin organization, but it is still unclear how epigenetic modifications 
determine chromatin higher-order organization. In this dissertation, I will describe my 
work addressing the question of how chromatin organization is controlled by epigenetic 
factors and how this organization plays a role during the process of cellular 
differentiation during development and disease etiology. More specifically, I have 
focused on the role of MeCP2, an epigenetic factor in chromatin organization. 
 
In the first section of this introductory chapter, I provide a brief summary of what is 
currently known about chromatin organization. In the second section I briefly describe 
what are the epigenetic modifications of chromatin. In the third section I introduce the 
molecules that read this epigenetic information. In section four, I describe the role 
MeCP2 plays during differentiation. Finally I give an overview of the involvement of 
MeCP2 in causing a neurological disease called Rett syndrome. 
 
1.1. Chromatin organization and assembly 
In the nucleus of eukaryotic cells, DNA is compacted, folded and organized within 
chromatin. The term “chromatin” (from the Greek word color), was first used to describe 
nuclear structures, which were observed by staining cells with aniline dyes (Flemming, 
1882). Chromatin was subdivided further into “heterochromatin” and “euchromatin”. The 
term heterochromatin was used to describe chromosome portions which remained in a 
mitotic, condensed state in the interphase nucleus as revealed by light microscopy of 
moss thallus cells stained with carmine acetic acid (Heitz, 1928).  
The fundamental basic structure of chromatin is called nucleosome (Figure 1). It 
consists of an octamer made from a double tetramer of the four core histones, H2A, 
H2B, H3 and H4. 146 bp long DNA is coiled around these core histones (reviewed in 
(Olins and Olins, 2003). Nucleosomes complexed with linker histone H1 are called 
chromatosome. Chromatosomes are connected by 20-60 bp of DNA and form the 11nm 
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fiber. This is known as “beads-on-a-string“ structure. (Olins and Olins, 1974) and is the 
1st higher order chromatin conformation. The “beads-on-a-string“ structure coils into a 
30nm diameter possibly helical structure, which is known as 30nm fiber or “solenoid 
structure“ (reviewed in (Horn and Peterson, 2002)) (Figure 1). Further higher order 
conformations such as “loop domain model” have also been proposed (discussed by 
(Cook, 2001)) (Figure 1). 
 
 
 
 
Figure 1. Schematic model of the levels of chromatin organization.  
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Chromatin organization is not only important for compaction of DNA into the nucleus, 
but is also important for controlling several genomic functions like DNA transcription, 
replication, repair and recombination. Modifications of chromatin proteins and DNA are 
referred to as epigenetic modifications. 
 
1.2. Epigenetic modifications of chromatin 
Epigenetics are a set of mechanisms and phenomenon that affect the phenotype of an 
organism or cell without changing the genotype. It refers to features such as chromatin 
and DNA modifications that are stable over multiple rounds of cell division but do not 
involve changes in the underlying DNA sequence of the organism (Wu and Morris, 
2001). Epigenetic modifications regulate gene expression which in turn is important for 
differentiation. Thus while most of these features are considered dynamic over the 
course of development in multicellular organisms, some epigenetic features show 
transgenerational inheritance and are passed from one generation to the next. 
 
 
 
Figure 2. Epigenetic modifications and higher order chromatin organization in the cell. 
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Epigenetic processes include genomic imprinting, gene silencing, X chromosome 
inactivation, position effect variegation, reprogramming, maternal effects, regulation of 
histone modifications and heterochromatin. The molecular basis of epigenetics  
involves modifications to DNA and chromatin proteins e.g. histones (Figure 2). 
 
1.2.1. Histone modifications  
Histones constitute the basic components of nucleosomes and as such are a prime 
candidate for epigenetic modification (reviewed in (Bhaumik et al., 2007). The N-
terminal “tails” are very rich in positively charged amino acids like lysine and arginine, 
which interact with the DNA backbone as well as with core regions of nucleosomes, and 
lead to chromatin compaction. The net charge of the histone tails is changed when 
these residues are covalently modified, leading to a change in their capacity to interact 
with DNA. Multiple modifications of histones like acetylation, methylation, 
phosphorylation, ubiquitination, sumoylation, poly(ADP-ribosyl)ation have been 
described. Here, I will briefly summarize acetylation and methylation. 
 
The acetylation and deacetylation of histones H3 and H4 is catalyzed by enzymes 
termed histone acetyl-transferases (HATs) or histone deacetylases (HDACs) 
respectively. Histone tails are normally positively charged due to amine groups present 
on their lysine and arginine amino acids. These positive charges help the histone tails to 
interact with and bind to the negatively charged phosphate groups on the DNA 
backbone. Acetylation, which occurs normally in a cell, neutralizes the positive charges 
on the histone by changing amines into amides and decreases the ability of the histones 
to bind to DNA. Histone deacetylases removes those acetyl groups, restoring positive 
charges to the histone tails and encouraging high-affinity binding between the histones 
and DNA backbone. Histone acetyl transferases (HAT) acetylate conserved lysine 
amino acids on histone proteins by transferring an acetyl group from acetyl CoA to 
lysine to form ?-N-acetyl lysine. Histone acetylation is generally linked to transcriptional 
activation and is associated with euchromatin. Initially, it was thought that acetylation of 
lysine neutralizes the positive charge normally present, thus reducing affinity between 
histone and (negatively charged) DNA which renders DNA more accessible to 
transcription factors. More recently, it has emerged that lysine acetylation and other 
posttranslational modifications of histones generate binding sites for specific protein-
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protein interaction domains, such as the acetyl-lysine binding bromodomain. In contrast, 
histone deacetylases (HDAC) remove acetyl groups from ?-N-acetyl lysine amino acids 
on histones, causing the DNA to wrap more tightly around the histones. This change 
interferes with gene transcription by blocking access by transcription factors. The overall 
result of histone deacetylation is a global (non specific) reduction in gene expression.  
 
Histone methylation (Figure 2) involves the addition of methyl groups to N-terminal 
lysines (Lachner et al., 2003)  and arginines (Stallcup, 2001) of histone H3 and H4. This 
modification does not have an affect on the charge of the modified histones (Strahl and 
Allis, 2000) and has been found to be associated with both transcriptional activation and 
silencing. Methylation at K4 and K36 of histone H3 as well as arginine is associated with 
transcriptional activity, whereas methylation at K9 and K27 of H3 and K20 of H4 are 
associated with silencing (Peters et al., 2003). Different enzymes are associated with 
methylation marks in eu- and heterochromatin. Histone methyl transferases (HMT), 
histone-lysine N-methyl transferases and histone-arginine N-methyl transferases, are 
enzymes which catalyze the transfer of one to three methyl groups from the cofactor S-
Adenosyl methionine to lysine and arginine residues of histone proteins. G9a is shown 
to be involved in di-methylation of H3K9 in euchromatin (Tachibana et al., 2001), while 
Suv39h1/2 is thought to be responsible for tri-methylation of H3K9 in heterochromatin 
(Peters et al., 2003).  
 
1.2.2. DNA modifications 
The direct modification of DNA, specifically DNA methylation, is another important 
aspect of epigenetics (Figure 2) that has been shown to influence gene expression, by 
changing chromatin structure.  This process is evolutionarily conserved and has been 
observed in many organisms from bacteria to mammals. Methyl groups are added on 
either cytosines or adenines, at the C5 or N6 position, resulting in the formation of either 
5-methyl cytosines (5mC) or N6-methyladenine (N6mA). Methylation in prokaryotes is 
associated with a protective mechanism that prevents the host DNA from restriction 
endonucleases, which are used to digest the foreign DNA (Srinivasan and Borek, 1964). 
Eukaryotic DNA is primarily methylated at cytosine residues. In humans, it is estimated 
that approximately one percent of the DNA bases are methylated at 5-methyl cytosines 
(Kriaucionis and Bird, 2003) 
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DNA methylation is essential for embryonic development, since mice lacking DNMTs do 
not survive (Li et al., 1992; Okano et al., 1999). DNA methylation is also important for X 
chromosome inactivation (XCI) in females. Furthermore, DNA methylation is important 
for direct transcriptional silencing and suppression of recombination. In humans, several 
DNMTs (DNA methyl transferases) have been found (reviewed in (Cheng and 
Blumenthal, 2008). Out of these DNA methyl transferases 1, 3a, and 3b (DNMT1, 
DNMT3a, DNMT3b) are associated with the process of DNA methylation. It is thought 
that DNMT3a and DNMT3b are the de novo methyl transferases that set up DNA 
methylation patterns early in development, while DNMT1 maintains these patterns, 
copying them to the daughter strands during DNA replication. In both cases, SAM (S-
adenosyl-L-methionine) serves as a methyl-group donor. DNMT3L is a protein that is 
homologous to DNMT3a and 3b but has no catalytic activity. Instead, it assists the de 
novo methyl transferases by increasing their ability to bind to DNA and stimulates their 
activity. Finally, DNMT2 has been identified as an "enigmatic" DNA methyl transferase 
homolog, containing all 10-sequence motifs common to all DNA methyl transferases; 
however, DNMT2 does not methylate DNA (Okano et al., 1998) but instead methylates 
cytosine 38 in the anticodon loop of tRNA (Goll et al., 2006; Rai et al., 2007). 
Resetting of methylation marks during mammalian embryonic development is necessary. 
Reprogramming refers to erasure and remodeling of epigenetic marks, such as DNA 
methylation, during mammalian development (Reik and Walter, 2001). While many 
genes are highly methylated in sperm DNA (Groudine and Conkin, 1985; Rai et al., 
2007)genes are often less methylated in oocytes (Monk et al., 1987; Sanford et al., 
1987). After fertilization the paternal and maternal genomes are once again 
demethylated and remethylated (except for differentially methylated regions associated 
with imprinted genes). This reprogramming is likely required for totipotency of the newly 
formed embryo and erasure of acquired epigenetic changes (Huppke et al., 2000; Kafri 
et al., 1992; Sanford et al., 1987). After implantation, the DNA of the extra embryonal 
membranes (yolk sac and placenta) becomes dramatically demethylated, while the DNA 
of the fetal tissues is subjected to a de novo methylation process (Monk et al., 1987; 
Razin and Szyf, 1984; Sanford et al., 1987). During the process of gametogenesis the 
primordial germ cells must have their original biparental DNA methylation patterns 
erased and re-established based on the sex of the transmitting parent (Chaillet et al., 
1991; Gomperts et al., 1994; Kafri et al., 1992). In vitro manipulation of pre-implantation 
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embryos has been shown to disrupt methylation patterns at imprinted loci (Mann et al., 
2003). 
 
1.3. Molecules that read epigenetic information 
Epigenetic information in the form of DNA and histone modifications needs to be 
interpreted into gene expression/repression programs. Methylated histone H3 and 
methylated cytosines are associated with gene silencing and are recognized by the 
members of heterochromatin protein 1 (HP1) family and the methyl CpG binding protein 
family (MBD), respectively. Both these families of chromatin associated factors have 
been connected with transcriptional repression. 
 
1.3.1. Heterochromatin Protein 1  
Heterochromatin protein 1, a major component of heterochromatin was first identified in 
Drosophila melanogaster (James and Elgin, 1986) where it acts as a dominant 
suppressor of position effect variegation (PEV). HP1 belongs to a highly conserved 
family of chromatin proteins, with homologues that are found from fission yeast (Swi6, 
Chp2 and Chp1) to humans (HP1?, HP1? and HP1?) (Huisinga et al., 2006). The 
CBX (chromobox) class of genes encodes the HP1 family of protein. In humans, HP1?, 
HP1? and HP1? are encoded by chromobox homolog (CBX5), 1(CBX1) and 3(CBX3) 
respectively.  
Three functional domains have been characterized in HP1. First, is the chromodomain 
(CD) at the N terminus. This domain is highly conserved and binds to di and tri-
methylated K9 at histone H3 (Aasland and Stewart, 1995). Second, is the 
chromoshadow domain (CSD) at the carboxy terminus. It is associated with homo 
and/or heterodimerization and interaction with other proteins. Third, is the variable linker 
or hinge region. It is present in between chromodomain and chromoshadow domain. It 
contains a nuclear localization signal (Figure 3). 
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Figure 3. Scheme and alignment of different isomers of human heterochromatin protein1. ‘*’ indicates 
positions which have a single fully conserved residue. ‘:’ indicates that either of the strong groups (STA, 
NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW) is conserved. ‘.’ Indicates either of the weak 
groups (CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, FVLIM, HFY) is 
conserved. These are all the positively scoring groups that occur in the Gonnet Pam250 matrix. The 
strong and weak groups are defined as strong score >0.5 and weak score =<0.5 respectively. 
 
Purified chromodomain is found as a monomer, whereas chromoshadow domain can 
form dimers in solution (Brasher et al., 2000). Localization studies of the protein have 
suggested that HP1 is not only localized to heterochromatin but also to euchromatin 
regions (Horsley et al., 1996; Minc et al., 1999). Studies in mammalian cells have 
shown that HP1? and HP1?are mainly distributed at pericentric heterochromatin 
domains whereas HP1? is localized in discrete euchromatin sites (Minc et al., 1999).  
In addition to its binding to methylated K9 of histone H3, HP1 has been shown to 
interact with several other histone and non-histone proteins.  
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Figure 4. Summary of HP1 protein interactions. In parenthesis, is indicated the domain involved in 
interaction. CD (chromodomain), CSD (chromoshadow domain) and ND (not determined). 
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Table 1. Summary of HP1 protein interactions.  
Interacting partners Interaction 
domain 
Reference 
Kap-1/Tif1? (Kruppel box associated protein) CSD (Nielsen et al., 1999) 
CAF-1 p150 (chromatin assembly factor 1 p150 subunit) CSD (Murzina et al., 1999) 
TAFII130 (TATA-binding protein associated factor p130) CSD (Vassallo and Tanese, 2002) 
SP100 (nuclear auto antigen Speckled 100 kD) CSD (Seeler et al., 1998) 
Suv39H1  CSD (Melcher et al., 2000) 
Pc (polycomb) CSD (Yamamoto et al., 2004) 
ATRX (SWI2/SNF2 DNA helicase/ATPase) CSD (McDowell et al., 1999) 
Histone H4 CSD (Zhao et al., 2000) (Polioudaki et al., 
2001) 
PIM-1 (proviral integration site 1) CSD (Koike et al., 2000) 
Ki-67 (cell proliferation antigen of monoclonal antibody Ki-67) CSD (Scholzen et al., 2002) 
LBR (lamin B receptor) CSD (Ye et al., 1997) 
BRG1 (SWI/SNF related transcriptional activation) CSD (Nielsen et al., 2002) 
Ku70 (K 70 auto antigen) CSD, hinge (Song et al., 2001) 
MITR (myocyte enhancer factor 2 (MEF2)-interacting 
transcription repressor) 
hinge (Zhang et al., 2002) 
INCENP (inner centromere protein) hinge (Ainsztein et al., 1998) 
ORCI-6 (origin recognition complex 1-6) CD, CSD (Pak et al., 1997) 
Pc3 (cohesion subunit Pc3) CD (Nonaka et al., 2002) 
H3K9Me3 (trimethyl K9 histone H3) CD (Bannister et al., 2001) 
Histone H3 CD (Nielsen et al., 2001) (Polioudaki et 
al., 2001) 
LAP2β (lamin associated polypeptide 2 β) CD (Kourmouli et al., 2001) 
lamin B CD (Kourmouli et al., 2001) 
Hsk I/CDC7 (S. pombe homolog of CDC7/ cell division cycle 
7) 
ND (Bailis et al., 2003) 
RNA ND (Muchardt et al., 2002) 
Histone H1 ND (Nielsen et al., 2001) 
Rb (retinoblastoma) ND (Nielsen et al., 2001) 
Dnmt 3a, 3b (DNA methyl transferase 3a, 3b) ND (Bachman et al., 2001) 
 
The data above show that HP1 forms a web of protein interactions via multiple domains 
(Figure 4, Table 1).  
Furthermore, fluorescence photobleaching recovery experiments (FRAP) (Cheutin et al., 
2003) showed that HP1 binding to pericentric heterochromatin is not stable, but rather 
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highly dynamic. This allows for modifications to occur while maintaining a stable 
chromatin state. 
 
1.3.2. Methyl CpG binding proteins 
For quite sometime DNA methylation has been correlated with transcription repression. 
In the most direct way, methylation of cytosines (5mC) prevents the binding of basal 
transcriptional factors that require contact with cytosines in the major groove of the DNA 
double helix. A second indirect way methylation of cytosines can induce transcription 
repression is via methyl-CpG binding proteins. 
The methyl-CpG-binding protein family comprises MeCP2, MBD1, MBD2, MBD3 and 
MBD4, which share the conserved methyl-CpG-binding domain (Hendrich and Bird, 
1998) (Figure 5).   
 
MBD1 is the largest member of the family, around 50-70kDa and contains a sequence 
motif, the CXXC motif, shared with Dnmt1 (Cross et al., 1997). There are at least five 
splicing variants of the mRNA of human MBD1 (Fujita et al., 1999; Ng et al., 2000) and 
three variants in mice (Jorgensen et al., 2004). The major difference between them is 
the presence of either two or three CXXC cysteine rich regions. Unlike MeCP2, MBD1 
can repress transcription of methylated and unmethylated templates (Cross et al., 1997; 
Fujita et al., 1999). The solution structure of the MBD domain of MBD1 has been solved 
(Ohki et al., 1999). The structure of this domain is very similar to that of MeCP2. Though, 
in MeCP2, three solvent exposed hydrophobic residues have been predicted to directly 
contact the methyl groups in the major groove (Wakefield et al., 1999). In MBD1 
however, only one position out of these three contain a hydrophobic residue, the 
tyrosine 34. 
 
MBD2 is a 44-kDa protein with 414 amino acids. It binds to methylated DNA with its 
MBD domain, and it has also been shown to possess transcription repression activity. 
Out of these roughly amino acids 140-400 including the MBD are highly similar to MBD3 
(Hendrich and Bird, 1998). The N-terminal part of the protein consists largely of lysine 
and arginine repeats. MBD2b, lacking this amino terminal 140 amino acids has been 
reported to show a demethylase activity (Bhattacharya et al., 1999) although these 
results have not been confirmed. MBD2 interacts with the NuRD complex generating 
INTRODUCTION 
 
-12- 
the MeCP1 complex. This was the first methyl CpG binding activity, which was isolated 
in mammals (Meehan et al., 1989).  
 
 
 
Figure 5. Scheme of different members of methyl CpG binding family and alignment of their MBD. 
Symbols are as indicated in Figure 3. 
MBD3 is the smallest member of the family, around 30 kDa. It is the only member of the 
MBD family, which does not bind to methylated CpGs due to two amino acid 
substitutions within the MBD domain of MBD3 (Saito and Ishikawa, 2002). Some other 
vertebrates like Xenopus, Zebrafish have two MBD3 forms, one of which can bind to the 
methylated CpGs (Wade et al., 1999). The global demethylation event, characteristic of 
early mammalian development is absent in both Zebrafish (Macleod et al., 1999) and 
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Xenopus (Stancheva and Meehan, 2000). MBD3 is also a member of the NuRD co- 
repressor complex, which plays an important role in transcription silencing via histone 
deacetylation. MBD3 has been shown to be important during embryonic development 
(Hendrich et al., 2001).  
 
MBD4 is a 63-kDa protein that is not associated with histone deacetylase activity or 
transcription regulation. Its carboxyl terminal has homology to bacterial repair enzymes 
(Hendrich and Bird, 1998). MBD4 plays a major role in preventing the mutational risk, by 
transition of 5mC→T by deamination. The MBD domain of MBD4 binds to methylated 
CpG dinucleotides, but has preference for 5mC paired with TpG (Hendrich et al., 1999). 
The C-terminal glycosylase moiety present in MBD4 specifically removes Ts from G-T 
mismatches (Hendrich and Tweedie, 2003). It has been shown that MBD4-/- cells show 
a 3.3 fold increased C→T transition, compared to wild type (Millar et al., 2002; Wong et 
al., 2002).  
 
MeCP2 is the founding member of the MBD (methyl CpG protein binding) family (Lewis 
et al., 1992). MeCP2 is quite conserved among different family members (Figure 7). 
The crystal structure of MeCP2-MBD in complex with DNA (Ho et al., 2008) has been 
shown to be similar to the unliganded structure (Wakefield et al., 1999). The MBD has a 
wedge shaped structure, with one face of the wedge composed of a beta sheet and the 
other face consisting of the alpha helix and hairpin loop. Two main functional domains 
have been defined for MeCP2. The MBD domain, which is capable of binding to one or 
more symmetrically methylated CpGs (Nan et al., 1993). Recently, it has been shown 
that high affinity binding of MeCP2 to DNA requires AT rich sequences adjacent to CpG 
sites on DNA (Klose et al., 2005). The second well-characterized domain of MeCP2 is 
the transcriptional repression domain or TRD (Nan et al., 1997), which is required for 
large distance (2kb mRNA) transcriptional repression in vitro and in vivo. MeCP2 after 
binding specifically to methylated DNA recruits Sin3A and HDAC, which further 
deacetylates the tails of H3 and H4 histones. This deacetylation leads to compaction of 
chromatin and thus the chromatin becomes inaccessible to transcription factors. 
Silencing can be relieved by inhibition of histone deacetylases (Jones et al., 1998). 
MeCP2 interacts with several other proteins as summarized in (Figure 6). 
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Figure 6. Interaction of MeCP2 with other proteins. 
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MeCP2 is known to lower transcriptional noise, rather than acting as a global repressor. 
Further, recently it has been shown that the C-terminal domain of MeCP2 can also 
interact with unmethylated DNA (Nikitina et al., 2007a).  
 
MECP2 is expressed in different tissues as shown by Northern blot analysis (Coy et al., 
1999; D'Esposito et al., 1996; Reichwald et al., 2000; Shahbazian et al., 2002). The 
gene consists of 4 exons (Reichwald et al., 2000). In vivo MeCP2 exists in two 
alternatively spliced isoforms. MeCP2A/MeCP2e2 (Nan et al., 1993) and 
MeCP2B/MeCP2e1 (Mnatzakanian et al., 2004). MeCP2B/MeCP2e1 utilizes exon 1 of 
MeCP2, skips exon2, and uses full-length exons 3 and 4 and is the longer form of 
MeCP2. The larger transcript, which is found mostly in the brain (Kriaucionis and Bird, 
2003) is 10kb long, is composed of 1.5kb coding region and 8.5kb untranslated 3’ UTR 
region (Coy et al., 1999; Reichwald et al., 2000). MeCP2A/MeCP2e2 utilizes exon 2,3 
and 4 of MeCP2 gene. This shorter and more predominant form migrates as a 1.9 kb 
band. This form is mostly expressed in heart, kidney and skeletal muscle. 
To understand the function of MeCP2 in development, it is important to know in detail its 
changes during differentiation. 
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Figure 7. Alignment of MeCP2 from different species. Symbols are as indicated in figure 3.  
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1.4. Cellular differentiation and MeCP2 
In developmental biology the term differentiation is used to describe the diversification 
of pathways, wherein a less specified cell becomes a more specialized cell type. A cell 
that is able to differentiate into many cell types is known as pluripotent, while the cell 
that is able to differentiate into all cell types is called totipotent. Differentiation occurs 
numerous times during the development of a multicellular organism as the organism 
develops from a single zygote to a complex system of tissues and cell types. 
Differentiation is a common process in adults as well: adult stem cells divide and create 
fully differentiated daughter cells during tissue repair and during normal cell turnover. 
When a cell differentiates its size, shape, polarity, metabolic activity, and 
responsiveness to signals may change dramatically. These changes are largely due to 
highly controlled modifications in gene expression. With few exceptions, cellular 
differentiation does not involve a change in the DNA sequence itself. Thus, different 
cells can have very different physical characteristics despite having the same genome. 
Differentiation is driven by the activity of nuclear proteins that regulate transcription. 
During differentiation, proliferating cells eventually get committed, migrate, withdraw 
from cell cycle, and form neurons, myofibrils etc.  
Further it has been show that MeCP2 is involved in the differentiation of neuronal cells, 
in particular in the development and maintenance of dendritic spines, rather than in cell 
fate decision (Armstrong et al., 1995; Armstrong et al., 1998; Kishi and Macklis, 2004). 
Our studies in muscle differentiation, also point in a similar direction. Wherein, the level 
of expression of MeCP2 increases dramatically from myoblasts to myotubes (Brero et 
al., 2005). Though neurogenesis has been intensively studied in vivo, a reproducible in 
vitro differentiation system is still lacking. Moreover most of the existing cell lines are 
tumor derived. Therefore, we chose to use a well-established in vitro myogenic 
differentiation system to perform our studies.   
 
1.5. Rett syndrome and MeCP2 
Rett syndrome (RTT, OMIM: 321750) is a neurological disorder, first reported by Dr. 
Andreas Rett in 1966. It is the second most common mental retardation disease in 
females after Down’s syndrome with an incidence of one in every 10,000 to 15,000 
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females born. The females develop normally until 6 to 8 months of age and then show a 
progressive stop in development accompanied by regression of acquired skills. 
 
1.5.1. Clinical features of Rett syndrome patients 
Clinical features include deceleration of head growth, loss of purposeful hand 
movement, ataxia, acoustic features, seizures, stereotypic hand movements “hand 
wriggling” and respiratory dysfunction. 80% of RTT cases have been reported to be 
sporadic (Amir et al., 1999; Bienvenu et al., 2000; Buyse et al., 2000; Cheadle et al., 
2000; Huppke et al., 2000; Xiang et al., 2000). It is further characterized by loss of 
acquired motor and language skills, autistic features and stereotypical hand movements. 
 
1.5.2. Genetics behind Rett syndrome 
Familial occurrences suggested that RTT is an X-linked dominant disorder (Figure 8), 
with possible male lethality. Genetic mapping of such familial cases have identified 
chromosome X position q28 (Xq28) (Ellison et al., 1992; Sirianni et al., 1998). The 
mutation was mapped on the gene MECP2 (Amir et al., 1999). Due to X chromosome 
inactivation (XCI), each cell of the female body expresses only one of the X 
chromosome alleles. XCI is a random process. The severity of the disease in females 
depends on which cells the X chromosome having the wild-type gene was inactivated.  
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Figure 8. Localization of MECP2 gene, functional domains of the corresponding gene product and 
structure of the MBD domain. 
 
The majority of Rett mutations found on MECP2 are due to direct C→T conversions in 
CpG dinucleotides (Dragich et al., 2000). Sperm DNA is more highly methylated than 
same sequences in oocytes, because of the need for greater compaction. Also, 
methylated cytosines become converted to uracil, which is not easily identified by the 
repair machinery. Due to these reasons sperm DNA is liable to more mutations in a 
highly CG-rich gene such as MeCP2 (Thomas, 1996), and therefore females are more 
susceptible to RTT than males, as they get one of their X chromosomes from the 
paternal side. 
 
1.5.3. Genotype-phenotype correlations 
The studies done on genotype-phenotype correlations have yielded inconsistent results. 
Some groups showed that truncation mutations led to more severe symptoms as 
compared to missense mutations (Cheadle et al., 2000; Monros et al., 2001), however 
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others groups could not find such a correlation (Amir et al., 1999; Bienvenu et al., 2000; 
Huppke et al., 2000). This could be explained by the fact that in females there is random 
X chromosome inactivation, and the severity of the symptoms depends upon the 
number and types of cells having the mutated form of MeCP2 in the active X 
chromosome. Since in males, there is no XCI, the genotype-phenotype correlation could 
be clearer. Unfortunately, much less cases of RTT males have been reported. 
 
1.5.4. Mouse models for Rett syndrome 
The brain size of RTT patients and MeCP2 null mice is smaller than normal individuals 
(Armstrong, 1997; Chen et al., 2001). In the MeCP2 null mice, the hippocampus CA2 
neurons are quite smaller than the wild type. Also, the nuclei of the neurons throughout 
the CNS were noticeably smaller (Chen et al., 2001). In addition, in heterozygous 
female RTT brains, neurons in layer III and V of the frontal, motor and inferior temporal 
cortex were smaller, with shorter apical and basilar dendritic branches (Armstrong et al., 
1995; Armstrong et al., 1998). 
There has been substantial effort in the development of mouse models for Rett 
syndrome. These models have focused on firstly mimicking the clinical phenotypes 
seen in Rett patients. More recently, efforts have been made to rescue MeCP2 gene 
expression and restoration of MeCP2 function. The latter have the major drawback that 
induction of wild type MeCP2 in the context of a null genotype would rather not reflect 
the disease problem where a mutated gene product is present throughout. The different 
mouse genetic models and ensuing studies are summarized in Table 2. 
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Table 2. Studies of Rett syndrome using mouse models.  
Mouse model Short summary of the mouse model  Reference 
Null  
MeCP2 lacking male ES cells could not support development. 
 (embryonic lethality). 
(Tate et al., 1996) 
Null 
MeCP2 null mice were produced using Cre-LoxP recombination 
system to delete exon 3 of MeCP2 gene; mimics Rett syndrome; 
MeCP2 plays a role in mature neurons and its role is not 
restricted to immature neurons 
(Chen et al., 
2001) 
Null 
MeCP2 null mice were produced by Cre-LoxP recombination 
system to delete exon 3 and 4 of MeCP2 in ES cells; mimics 
Rett syndrome; MeCP2 is required for a stable brain function, 
rather than in brain development. 
(Guy et al., 2001) 
Truncated  
Mouse with a stop codon after codon 308, they called the 
mutated allele as MeCP2308; MeCP2 was localized to 
heterochromatin domain in vivo, but histone H3 was 
hyperacetylated. 
(Shahbazian and 
Zoghbi, 2002) 
Truncated 
MeCP2 308/X; X-chromosome inactivation (XCI) patterns were 
unbalanced in more than 60% of the animals, favoring 
expression of the wild type allele. 
(Young and 
Zoghbi, 2004) 
Null  
MeCP2 null mouse model produced by Cre-LoxP recombination 
system to delete exon 3 of MeCP2; looked on the olfactory 
system and found that posttranslational protein modifications 
play an important role and concluded that not only transcription 
should be considered but also the brain region and the age of 
the mouse and the posttranslational modifications should be 
considered. 
(Matarazzo and 
Ronnett, 2004) 
Heterozygous  
MeCP2 +/- female mice; showed that MeCP2 mutant neurons 
affect the development of nearby neurons and environment 
affects the level of MeCP2 expression in wild type cells. 
(Braunschweig et 
al., 2004) 
Transgenic 
Mouse model that transgenically expressed MeCP2, under 
control of an endogenous human promoter, by using a large 
insert of genomic clone from PAC, which contained a MeCP2 
locus. Even mild overexpression of protein can lead to 
symptoms like Rett syndrome. Thus the authors could show that 
MeCP2 levels are tightly regulated. 
(Collins et al., 
2004) 
Truncated 
MeCP2 308/Y; studied social behavior in mice and found that 
MeCP2 might regulate expression/ function of genes involved in 
social behavior. 
(Moretti et al., 
2005) 
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Truncated 
Male mouse with truncated MeCP2; displayed increased 
anxiety-like behavior and an abnormal stress response, similar 
to patients with RTT. The changes were associated with 
increased serum corticosterone levels. The results show that 
MeCP2 regulates Crh expression. 
(McGill et al., 
2006) 
Conditional 
tissue 
specific 
rescue 
MeCP2 gene is silenced by insertion of a lox-stop cassette in 
intron 2, which could be conditionally activated by Tamoxifen; 
mouse showed restoration of neuronal function by late 
expression of MeCP2 suggesting that Rett syndrome symptoms 
can be reversed. 
(Guy et al., 2007) 
Transgenic 
Mouse model that transgenically expressed MeCP2, HA-MeCP2 
transgene is downstream of an inducible promoter in the 
transgenic mice. The transgenic mice were further crossed with 
Mecp2-/+ females. Authors show that Rett-like behavior could be 
improved in Mecp2-/+ females by targeted gene re-introduction. 
(Jugloff et al., 
2008) 
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2. AIMS OF THE WORK 
Recently, our group and others have shown that large-scale heterochromatin 
organization takes place during terminal differentiation. In this work, I focused on two 
major non-histone markers of heterochromatin, MeCP2 and HP1 and their role during 
this process.  
 
Using an in vitro myogenic differentiation system, as the model system for the study, I 
investigated their expression levels, their interaction and their localization during 
differentiation. Furthermore, I tested whether HP1 plays a role in chromatin organization 
during cellular differentiation. Based on the outcome that MBD family members and not 
HP1 family members are involved in large-scale chromatin organization, I tested 
whether these pathways are redundant or synergistic. 
 
Furthermore, I have investigated the relevance of MeCP2 in vivo by testing the affect of 
a large series of MeCP2 mutations found in Rett syndrome. I have analyzed whether or 
not these MeCP2 mutations affect its capacity to bind to chromatin, the dynamics of its 
binding and its ability to cluster chromatin in vivo.
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3. RESULTS 
 
 
 
 
 
 
 
 
 
3.1. MeCP2 interacts with HP1 and modulates its 
heterochromatin association during myogenic 
differentiation 
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ABSTRACT
There is increasing evidence of crosstalk between
epigenetic modifications such as histone and
DNA methylation, recognized by HP1 and methyl
CpG-binding proteins, respectively. We have
previously shown that the level of methyl CpG-
binding proteins increased dramatically during
myogenesis leading to large-scale heterochromatin
reorganization. In this work, we show that the level
of HP1 isoforms did not change significantly
throughout myogenic differentiation but their loca-
lization did. In particular, HP1c relocalization to
heterochromatin correlated with MeCP2 presence.
Using co-immunoprecipitation assays, we found
that these heterochromatic factors interact in vivo
via the chromo shadow domain of HP1 and the first
55 amino acids of MeCP2. We propose that this
dynamic interaction of HP1 and MeCP2 increases
their concentration at heterochromatin linking
two major gene silencing pathways to stabilize
transcriptional repression during differentiation.
INTRODUCTION
Post-translational modiﬁcations of chromatin such as
histone and DNA methylation are recognized by epige-
netic regulators HP1 (heterochromatin protein 1) and
MeCP2 (methyl CpG-binding protein 2) respectively and
play an important role in transcriptional regulation. These
non-histone chromatin factors read the epigenetic marks
and translate them into inactive chromatin states.
MeCP2 is a member of a family of proteins, which
share a conserved methyl cytosine-binding domain (MBD)
that recognizes methylated CpG dinucleotides (1).
Moreover, MeCP2 contains a nuclear localization signal
[NLS; (2)] and a transcriptional repression domain
(TRD), which binds a corepressor complex containing
mSin3a and histone deacetylases [HDACs; (3)].
HP1 proteins are conserved from yeast to humans (4)
and recognize histone H3 trimethylated at the lysine
9 position [H3K9Me3; (5,6)]. In mammals, three isoforms
viz a, b, g have been identiﬁed (7,8). Functionally, three
domains have been deﬁned in HP1(s). The chromodomain
[CD; (9)]and the chromo shadow domain [CSD; (10)] are
highly conserved and are linked by the poorly conserved
hinge domain. The CD has been shown to be important
for binding methylated histones, while the CSD is
known to interact with several proteins (11) as well as
mediate homo (12) and heterodimerization of HP1
isoforms (13). The hinge domain interacts with DNA
(14) and RNA (15).
In mouse cells, both HP1 and MeCP2 accumulate
at pericentric regions of chromosomes organized into
chromocenters, which play an important role in epigenetic
gene regulation possibly by creating silencing compart-
ments within the nucleus. Recently, we have shown that
the level of MeCP2 as well as of MBD proteins starkly
increased during myogenic diﬀerentiation concomitant
with large-scale chromatin reorganization (16). To inves-
tigate a potential crosstalk between both epigenetic
regulators, we analyzed the amount and localization of
HP1 with respect to MBD proteins during cellular
diﬀerentiation. We found that although the level of HP1
proteins does not change dramatically, there is spatial
relocalization of HP1 (especially HP1g) during myogenesis
from a more diﬀused distribution to a focal enrichment at
pericentric heterochromatin. Furthermore, this redistribu-
tion to heterochromatin correlates with MeCP2 and
MBD1 protein presence. We also demonstrate that HP1
and MeCP2 interact physically with each other,
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strengthening the argument that they cooperate in the
formation of repressive subnuclear compartments
involved in epigenetic gene silencing.
MATERIALS AND METHODS
Expression plasmids
The following HP1 plasmids were used: GFP-tagged
full-length human HP1a/HP1b/HP1g (17); YFP-tagged
deletion mutants of human HP1a/HP1b/HP1g and
full-length human HP1a/HP1b tagged with DsRed2 (18).
To construct a DsRed2 fusion of HP1g, the BamHI–
HindIII fragment of GFP-HP1g containing HP1g was
subcloned into BglII–HindIII site of pDsRed2-C1
(Clontech). MeCP2 constructs used were GFP/YFP/
mRFP1-tagged full-length and deletion mutants of rat
MeCP2 (16). MeCP2Y.6 and MeCP2G.7 were constructed
by subcloning XhoI–HindIII and XhoI–PstI fragments
of MeCP2 from MeCP2Y into pEYFP-N1and
pEGFP-N1 (Clontech) cut with the same restriction
enzymes, respectively. pEGFP-N1 (Clontech) was used
as a control.
Cell culture and transfection
Pmi28 mouse myoblast cells (MB) were cultured as
described in (19), transfected using Transfectin (Biorad)
and diﬀerentiated as described before (16). Diﬀerentiated
cultures include syncitial myotubes (MT) and unfused
myocytes (MC).
HEK293-EBNA human cells (Invitrogen) were main-
tained in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum at 378C with
5% CO2. 4 105 HEK293-EBNA cells plated onto
100mm diameter culture dishes were transfected using
PEI (poly-ethyleneimine 25 kDa from Polysciences
1mg/ml in ddH2O, neutralized with HCl). For transfec-
tion 500 ml of DMEM without serum, 12 mg of DNA and
50 ml of PEI were mixed well, incubated for 10min at
room temperature, vortexed and added to the cells
dropwise. The culture was incubated at 378C overnight,
next day cells were washed in PBS, pelleted and used
for co-immunoprecipitation assays.
Immunofluorescence analysis and microscopy
Proliferating and diﬀerentiated Pmi28 cultures were
ﬁxed in 3.7% formaldehyde/PBS and permeabilized with
0.5% TritonX-100/1XPBS and immunostained as
described in (20). Primary antibodies used were: mouse
monoclonal anti-HP1 isoform-speciﬁc antibodies
(Chemicon), rabbit polyclonal anti-MeCP2 (Upstate)
and anti-MBD1 (Santa Cruz) antibodies. Secondary
antibodies used were: anti-mouse IgG-Cy5, anti-rabbit
IgG-FITC (Jackson Immuno Research). Samples were
counterstained with DAPI and examined on a Zeiss
Axiovert 200 using 40 and 63 objectives. Images were
acquired with a PCO Sensicam QE cooled CCD camera
using Zeiss Axiovision V.3 software and processed with
Adobe Photoshop. To quantify the correlation between
HP1g localization at chromocenters and presence of
MeCP2 or MBD1, we analyzed 375 MB cells; 71 cells
with positive staining for MeCP2; 99 cells with positive
staining for MBD1; 125 cells transfected with MeCP2-
GFP and 345 MT nuclei from two independent experi-
ments done in triplicate. The mean and SDs were plotted
using Microsoft Excel software (Figure 2).
Immunoprecipitation and western blot analysis
Diﬀerentiated and non-diﬀerentiated Pmi28 cells were
grown on p100 culture dishes, boiled in Laemmli sample
buﬀer and analyzed on western blots (Figure 1).
Immunoprecipitations (Figures 3 and 4) were done as
described before (21). The following primary antibodies
were used: rabbit polyclonal anti-lamin B [kind gift of
R.Bastos; (22)], rabbit polyclonal anti-H3K9Me3
(Upstate), rabbit polyclonal anti-MeCP2 (Upstate), chro-
matographically puriﬁed rabbit IgG (Organon Teknika),
mouse monoclonal anti-HP1a/HP1b/HP1g (Chemicon),
rabbit polyclonal anti-histone H3 (Upstate), mouse
monoclonal anti-GFP (Roche), GFP binder (23), anti-
mRFP1 rabbit polyclonal antiserum. Secondary anti-
bodies used were: anti-mouse IgG HRP (Amersham)
and anti-rabbit IgG HRP (Sigma). Immunoreactive
signals were visualized using an ECL plus Detection kit
(Amersham) and recorded using a luminescence imager
(Luminescent Image Analyzer LAS-1000, Fuji). To
compare the amounts of the diﬀerent proteins in
proliferating and diﬀerentiated myogenic cultures,
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Figure 1. Level of HP1 proteins during diﬀerentiation. (A) Schematic representation of myogenesis. (B) Western blot analysis of the level of HP1
isoforms and of HP1-binding site on chromatin (H3K9Me3) in MB versus MC/MT. Lamin B and histone H3 are taken as controls for equal nuclear
protein amounts and for total histone H3, respectively. (C) Quantitative analysis of western blots. Error bars indicate SDs.
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quantiﬁcation of the recorded signals was done with the
Image Gauge Ver.3.0 software (Fuji). Equal sized
boxes were made around the recorded signals and for
calculating the background. Integrated pixel intensity was
measured for each band and the respective back-
ground signal was subtracted. Signals were normalized
to the loading control (lamin B or histone H3) and the fold
diﬀerence between the normalized signals in diﬀeren-
tiated versus proliferating cultures was calculated. The
mean and SDs were calculated from three independent
experiments and plotted using Microsoft Excel software
(Figure 1).
RESULTS AND DISCUSSION
Level of HP1 isoforms remains mostly constant
during myogenesis
During cellular diﬀerentiation progressive inactivation
of the genome occurs in parallel with the activation of
tissue-speciﬁc gene expression patterns (24). We have
shown that the level of methyl CpG-binding protein
Figure 2. Pericentric heterochromatin association of HP1g increases
during diﬀerentiation and correlates with the presence of MeCP2 and
MBD1 proteins. (A) Cells were stained with HP1g and MeCP2-speciﬁc
antibodies and DNA counterstained with DAPI, highlighting the
chromocenters. In the upper panels, overview images and below them
representative magniﬁed MB cells are shown, of which only the MeCP2
positive cell has HP1g accumulated at chromocenters. The lower panels
show an overview of a diﬀerentiated culture, with most nuclei having
HP1g at chromocenters. Scale bar: 20 mm. (B) Percentage of cells with
HP1g at pericentric heterochromatin and correlation with MeCP2 and
MBD1 proteins. Error bars indicate SD.
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Figure 3. MeCP2 interacts with HP1 in vivo. (A) Schematic representa-
tion of the fusion proteins. Numbers represent amino acid coordinates.
(B and C) HEK293-EBNA cells were transfected with the plasmids
indicated and extracts prepared the next day. Immunoprecipitations
were done using either anti-GFP (B) or anti-mRFP (C) antibody. (D)
Extracts from MB and MT were subjected to immunoprecipitation
using the antibodies, as indicated. Input (I) and bound (B) fractions
were loaded in the percentages mentioned and analyzed by western
blotting using anti-HP1g (B, D) or anti-GFP (C).
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dramatically increased during muscle diﬀerentiation and
induced large-scale aggregation of pericentric heterochro-
matin (16). A second major pathway associated with
transcriptional silencing is mediated by HP1 binding of
histone H3K9Me3. We therefore investigated whether the
level of the diﬀerent HP1 isoforms varied during cellular
diﬀerentiation using a well-established in vitro culture
system for myogenesis (Figure 1A). Pmi28 mouse myo-
blasts (MB) were induced to diﬀerentiate by incubation in
horse-serum-containing medium. After three to four days,
cells fused to form post-mitotic multinucleated myotubes
(MT). These cultures still contained mononucleated
not fully diﬀerentiated cells termed myocytes (MC).
We quantiﬁed the level of HP1 in proliferating versus
diﬀerentiated cell extracts by western blot analysis and
normalized it to lamin B level as a loading control
for nuclear proteins. The level of HP1a, b, g remained
almost constant during diﬀerentiation (Figure 1B and C).
However, the fraction of histone H3 that was
trimethylated at lysine 9 position (H3K9Me3) increased
about 3-fold in diﬀerentiated cells.
Association of HP1c with heterochromatin increases
during differentiation and correlates with methyl
CpG-binding protein presence
Previous studies have reported a cell cycle stage and
isoform-speciﬁc localization of HP1 (18). To address
this possibility, we examined the in situ localization of the
HP1 isoforms as well as H3K9Me3 by immunoﬂuores-
cence staining during myogenic diﬀerentiation. Pericentric
heterochromatin organized in chromocenters was
highlighted by counterstaining with the DNA dye
40,6-diamidino-2-phenylindole (DAPI). We found that
the level of association of HP1 with pericentric hetero-
chromatin diﬀered between isoforms and changed during
diﬀerentiation. While HP1a protein could be found
accumulated at pericentric heterochromatin in most of
the MBs (89%; Supplementary Figure 1), HP1b did not
show such an accumulation (data not shown) and HP1g
showed only a weak heterochromatin accumulation in
about half of the MBs (61%; Figure 2). This weak
accumulation was not due to the absence of H3K9Me3,
since chromocenters of all MBs stained clearly positive for
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Figure 4. MeCP2 interacts via its N-terminal domain with the CSD domain of HP1. Schematic representation of the fusion proteins. Numbers
represent amino acid coordinates. HEK293-EBNA cells were transfected with the plasmids indicated. Immunoprecipitations were done using either
anti-mRFP or anti-GFP antibody. Input (I) and bound (B) fractions were loaded in the percentages mentioned and analyzed by western blotting
using anti-GFP or anti-HP1g (shown here is the endogenous HP1g).
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this histone modiﬁcation (Supplementary Figure 2) and is
consistent with earlier reports showing HP1g mostly
excluded from constitutive heterochromatin (25). We can
also rule out epitope masking (26), as in the same
population of MBs, there were cells where HP1g staining
was detected at chromocenters (Figure 2A magniﬁed
nucleus). The fraction of MT nuclei with HP1a and g
accumulated at heterochromatin increased to 100 and
90%, respectively (Supplementary Figure 1 and Figure 2).
In contrast, upon diﬀerentiation there was no major
change in the distribution of HP1b (data not shown) even
though there was an increase in the level of its binding site
H3K9Me3 (Figure 1). We reasoned therefore, that this
increase in heterochromatin association could depend on
diﬀerentiation-speciﬁc factors other than the histone
methylation mark per se. Since MeCP2 and other MBDs
are present in a few MB only but increase during
diﬀerentiation and label almost all chromocenters in MT
(16), we tested whether the change in heterochromatin
association of HP1g was correlated to MBD protein.
Indeed we found a clear correlation of HP1 heterochro-
matin association in MB and the presence of either
MeCP2 or MBD1. Almost all MeCP2 or MBD1 positive
MB contained HP1a (100%) and HP1g (95%) at
chromocenters (Figure 2 and Supplementary Figure 1).
Furthermore, 96 and 94% of MB cells ectopically
expressing MeCP2-GFP fusion had HP1g and HP1a
accumulation at pericentric heterochromatin (Figure 2B
and Supplementary Figure 1B). Altogether, these data
showed that the chromocenter association of HP1 with
particular emphasis for HP1g clearly increased upon
myogenic diﬀerentiation and was positively correlated
with the presence of MeCP2 and MBD1.
MeCP2 interacts via its N-terminal domain with
the chromo shadow domain of HP1
Since the accumulation of HP1 at chromocenters corre-
lated with the presence of MBD proteins at these sites, we
tested whether they could physically interact. HEK293-
EBNA cells, which express HP1 proteins, were transfected
with plasmids coding for GFP, GFP-tagged MeCP2 or
GFP-tagged HP1 (Figure 3A). Twelve hours later, cells
were lysed and immunoprecipitations performed with an
anti-GFP-speciﬁc antibody fragment [GFP binder; (23)].
Input and bound fractions were analyzed on western blots
for precipitated GFP-tagged protein (data not shown) and
for co-precipitated endogenous HP1g protein. HP1g did
not bind to GFP alone but was co-precipitated with
MeCP2-GFP (Figure 3B) and the same was true for HP1a
and b (data not shown). Since HP1a, b and g have been
shown to form homodimers (12,13) as well as hetero-
dimers [HP1a-g; (12)], [HP1a-b; (27)], we reproduced this
data as a positive control for our co-immunoprecipitation
conditions. Moreover, the fraction of HP1g bound to
HP1a was comparable with the amount bound to MeCP2
(Figure 3B). Using a mRFP-tagged MeCP2, we
co-immunoprecipitated GFP-tagged HP1a, b and g
(Figure 3C). MeCP2-GFP proteins could likewise immu-
noprecipitate DsRed2-tagged HP1s (Figure 4 and data not
shown) showing that the interaction of HP1 with MeCP2
was independent of the tags. Further, we tested whether
endogenous HP1 and MeCP2 could interact. We per-
formed immunoprecipitations using anti-MeCP2 antibody
on Pmi28 MBs (expressing low level of MeCP2) and MTs
(expressing higher level of MeCP2) (16). Indeed, the rabbit
anti-MeCP2 antibody but not the control rabbit IgG
could co-precipitate HP1g from MT extracts. Finally, to
test whether MeCP2 could directly interact with HP1, we
used GST pull down assays. Recombinant MeCP2
puriﬁed from bacteria was incubated with glutathione
agarose coupled GST or GST-HP1g (Supplementary
Figure 3). While no MeCP2 protein was detected in the
GST-bound fraction, GST-HP1g was able to speciﬁcally
pull down MeCP2. In summary, these results showed that
MeCP2 and HP1 interact in vivo and at a level comparable
to the dimerization of HP1 proteins.
The N terminus of HP1 contains the H3K9Me3-binding
site (5) while the C terminus mediates dimerization of HP1
as well as interaction with other proteins (11,28). To test
which domain would be involved in the interaction with
MeCP2, we co-transfected HEK293-EBNA cells with
plasmids coding for MeCP2-mRFP and with diﬀerent
YFP-tagged deletion constructs of HP1 isoforms coding
either for the CD or the CSD. Co-immunoprecipitation
assays demonstrated that the CSD of HP1s was necessary
and suﬃcient for binding to MeCP2 in vivo (Figure 4 and
data not shown). The CSD of HP1 has previously been
shown to be important for the interaction of HP1 with
other nuclear proteins (11). We then investigated which
domain of MeCP2 binds to HP1 by using a series of
ﬂuorescently tagged deletion constructs of MeCP2. The
results indicate that amino acids 1–55 of MeCP2 are
primarily involved in binding HP1 (Figure 4), though
weaker binding could be detected with other regions of
MeCP2 as well (Supplementary Figure 4). We conclude
that MeCP2 and HP1 interact via the CSD of HP1 and the
N-terminal domain of MeCP2.
The domains of MeCP2 that have been better function-
ally characterized are the MBD, the transcriptional
repressor domain (TRD) and the overlapping Sin3a
co-repressor domain (coRID), all of which are in the
central part of MeCP2 (29). Our data now implicate the
N-terminal region before the MBD in binding to HP1,
suggesting a direct physical link between the factors
translating DNA and histone methylation. On the one
hand, MeCP2 recognizes methyl CpGs and interacts with
DNA methyltransferase 1 (30). On the other hand, HP1
binds to H3K9Me3 and associates with the histone H3K9
methyltransferase [Suv39h1; (31)]. Our data showing that
HP1 and MeCP2 interact with each other interconnects
these two major epigenetic pathways. Most recently, HP1
was also reported to interact with Dnmt1 (32). It is
noteworthy that another MBD protein, MBD1 has been
reported to interact with HP1a via the MBD (33). Since
other MBDs (Figure 2 and Supplementary Figure 1) were
also able to enhance the accumulation of HP1 at hetero-
chromatin, any single MBD knockout would not be
expected to disrupt it. In line with this, we have previously
shown that other MBDs have overlapping functions and
knockout of MeCP2 alone did not aﬀect heterochromatin
reorganization during myogenic diﬀerentiation (16).
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Signiﬁcantly, we found that the heterochromatin associa-
tion of HP1g increased during diﬀerentiation and that this
was correlated with either MeCP2 or MBD1 presence. The
diﬀerentiation-speciﬁc increase of the MBD proteins could
enhance HP1g binding to constitutive heterochromatin,
which would then recruit histone H3K9 methyltrans-
ferases leading to higher levels of H3K9 methylation. In
Suv39h1/2 double knockout cells where H3K9 methyla-
tion at chromocenters is abrogated, MeCP2 still induced
clustering (16), indicating that its interaction with HP1 is
not required for its function in large-scale chromatin
organization. We further propose that the multiple
interactions of these factors with chromatin and with
each other generate subnuclear silencing compartments,
which stabilize the diﬀerentiated phenotype by reducing
transcriptional noise. Individually these interactions are
transient but their cumulative eﬀect at heterochromatin
increases the local concentration of repressing factors and
thereby the eﬃciency of gene silencing.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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 SUPPLEMENTARY INFORMATION 
Figure S1 
Pericentric heterochromatin association of HP1? increases during differentiation and 
correlates with the presence of MBD proteins. (A) Cells were stained with HP1? and 
MeCP2 specific antibodies and DNA counterstained with DAPI, highlighting the 
chromocenters. The upper panel shows representative MB cells and the lower panel an 
overview of a differentiated culture. Scale bar: 20 ?m. (B) Percentage of cells with HP1? 
at pericentric heterochromatin and correlation with MBD protein presence. 
HP1? protein could be found accumulated in chromocenters of 89% of MB (N= 131 
cells). In contrast, the fraction of MT nuclei with HP1? accumulated at heterochromatin 
increased to 100% (N= 100 cells). Indeed we found a correlation of HP1 heterochromatin 
association in MB and the presence of either MeCP2 or MBD1 with all MeCP2 or MBD1 
positive MB (N=42 and 28 cells, respectively) containing HP1? (100%) at 
chromocenters. Furthermore, 94% of MB cells ectopically expressing MeCP2-GFP 
fusion (N= 35 cells) had HP1? accumulation at pericentric heterochromatin. Altogether, 
these data showed that the chromocenter association of HP1? clearly increased upon 
myogenic differentiation and was positively correlated with the presence of MeCP2 and 
MBD1. 
 
Figure S2 
H3K9Me3 is present at chromocenters in MB and shows slight increase during 
differentiation. Cells were stained with H3K9Me3 specific antibody and DNA 
counterstained with DAPI. Scale bar: 20 ?m. 
 
Figure S3  
MeCP2 physically interacts with HP1?. Schematic representation of the constructs used 
in the experiment. GST and GST-HP1? were immobilized and incubated with purified 
MeCP2 (see supplemental method). Input (1%) and bound (15%) MeCP2 is shown. 
Whereas GST alone did not pull down MeCP2, an equivalent amount of GST-HP1? was 
able to specifically pull down MeCP2. 
 
Figure S4 
MeCP2 interacts preferentially via its N-terminal domain with the CSD domain of HP1. 
Schematic representation of the fusion proteins. Numbers represent amino acid 
coordinates. HEK293-EBNA cells were transfected with the plasmids indicated. 
Immunoprecipitations were done using anti-GFP antibody. Input (I) and bound (B) 
fractions were loaded in the percentages mentioned and analyzed by western blotting 
using anti- HP1? antibody. The ectopically expressed R-HP1 gamma binds to low and 
high affinity sites creating a competitive situation that reveals the preferential binding of 
the endogenous HP1 gamma protein to the N-terminus of MeCP2. 
 
Supplemental Method 
GST pull down assay 
BL21 competent cells were transformed with Glutathione S Transferase (GST) 
expressing plasmid pGex2T1 (Pharmacia) and pGST-HP1? (1). Single colonies from 
each were inoculated in 4ml of LB-Amp separately and incubated with overnight shaking 
at 37
o
C. 2ml of this culture was used to inoculate 200ml of LB-Amp media and further 
incubated till O.D600 reached to 0.6. 200μl of 1M IPTG (1mM final concentration) was 
added to each flask. After 3 hours of incubation, the culture was pelleted at 4000 rpm for 
30 min 4
o
C. All the further steps were done at 4
o
C unless otherwise stated. Cells were 
lysed using a high pressure homogenizer (EmulsiFlex-C5, Avestin) and extracts loaded 
on pre-equilibrated Glutathione Superflow Resin (Clontech) for 2 hours with shaking. 
Bound GST and GST-HP1? were checked on a gradient NuPAGE 4-12% Bis-Tris gel 
using MOPS SDS running buffer, and stained with Simply Blue Safe Stain (Invitrogen) 
along with purified MeCP2. MeCP2 (pTYB1) was produced and purified as described 
(2). Equal amounts of GST and GST-HP1? were then incubated with purified MeCP2 
overnight. Bound and flow through fractions were boiled in Laemmli sample buffer and 
analyzed on a gradient gel.  
1. Nielsen, A.L., Oulad-Abdelghani, M., Ortiz, J.A., Remboutsika, E., Chambon, P. 
and Losson, R. (2001) Heterochromatin formation in mammalian cells: 
interaction between histones and HP1 proteins. Mol Cell, 7, 729-739. 
2. Georgel, P.T., Horowitz-Scherer, R.A., Adkins, N., Woodcock, C.L., Wade, P.A. 
and Hansen, J.C. (2003) Chromatin compaction by human MeCP2. Assembly of 
novel secondary chromatin structures in the absence of DNA methylation. J Biol 
Chem, 278, 32181-32188. 
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Rett syndrome is a neurological, X chromosomal-linked disorder associated 
with mutations in the MECP2 gene. We have recently found that MeCP2 
induces large-scale heterochromatin remodeling. Therefore, we tested whether 
MeCP2 Rett mutations were affected in their ability to bind and induce 
aggregation of heterochromatin. We found that all 21 MeCP2 mutants analyzed 
accumulated at heterochromatin with the exception of R111G and surprisingly 
only a third of them were significantly affected. Furthermore, one third of all 
mutants showed also a significantly decreased ability to cluster 
heterochromatin. Yet both MeCP2 binding to and clustering of chromatin were 
not directly correlated but these two properties further allowed the separation 
of the mutants into two groups. Importantly, the mutations belonging to each 
group (binding or clustering impaired) segregated into two distinct surfaces of 
the MBD of MeCP2, thus ascribing novel chromatin functions of the MeCP2 
MBD affected in Rett syndrome. 
 
Rett syndrome (RTT, MIM 312750) is a postnatal neurological disorder, with an 
incidence of ~ 1/10,000 female births. The females develop normally until 6-18 
months of age, but after that, the growth is drastically slowed down, followed by the 
development of stereotypical hand movements, autistic behaviour, loss of speech 
and motoric skills, respiratory disorders, etc. Mutations in the chromosome Xq28 
region corresponding to the MECP2 gene have been shown to be linked to the 
disease 1. MeCP2 recognizes methylated cytosines via a highly conserved methyl 
cytosine-binding domain (MBD) and is concentrated in the densely methylated 
pericentric heterochromatin 2. Its ability to recruit transcription repression complexes 
and histone deacetylases via a region overlapping with its transcriptional repression 
domain (TRD) has been proposed to link both mechanisms of gene regulation by 
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stabilizing the heterochromatin state 3 . The mechanism(s) by which mutant MeCP2 
causes Rett syndrome is though thus far unknown. 
Several types of MECP2 gene mutations including deletions and also duplications 
have been found in Rett patients 4 5. A summary of MECP2 mutations along with their 
frequency is shown in Figure 1A (http://mecp2.chw.edu.au/cgi-
bin/mecp2/search/printGraph.cgi#MS). The most common are missense mutations 
(black lines in frequency plot), which cluster within the MBD. The structure 6 7 and 
conservation of this domain (in yellow) are depicted in Figure 1B and C, where the 
regions highlighted in blue recognize the methyl cytosines (displayed in white) and 
the residues making direct contacts with the cytosines are boxed in blue (Figure 1C). 
We have recently shown that the MBD of MeCP2 has the ability to reorganize and 
cluster pericentric heterochromatin 8 . Given that most Rett missense mutations 
affect this domain, we set out to investigate whether they were impaired on binding to 
and/or cluster heterochromatin. 
We selected Pmi28 mouse myoblasts as our cellular assay system. This cell line was 
used before to characterize the dose-dependent effect of wild type MeCP2 on the 
spatial organization of chromocenters and it expresses very low to undetectable level 
of endogenous wild type MeCP2 8. Moreover, it showed a stable and nearly normal 
karyotype (39, X0) (data not shown), resulting in moderate number of chromocenters 
compared to polyploid cell lines. Also, the stability of the karyotype minimized 
irreproducible variations of chromocenter number caused by variable numerical 
chromosome aberrations. 
We used mammalian expression constructs containing the mutant human MECP2e2 
isoform cDNAs fused at the C-terminus of the enhanced GFP coding sequence 9. All 
21 missense mutations within the MBD are highlighted in pink in Figure 1C and the 
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mutated forms of the wild type residues indicated below the sequence alignment. 
Intranuclear localization of the fusion proteins and the induction of chromocenter 
clustering in transfected cells were assessed by epifluorescence microscopy using 
the AT-selective DNA dyes Hoechst 33258, DAPI or TOPRO-3 to independently 
visualize pericentric heterochromatin. 
We first tested these MeCP2 Rett mutants for their protein accumulation at the 
chromocenters by taking a ratio of average mean intensity of protein bound at 
chromocenters versus nucleoplasm. The results indicate that all the mutant proteins 
showed an enrichment at chromocenters (ratio was greater than 1), but to very 
different extents (Figure 2). R111G mutant protein accumulated to the lowest extent. 
This mutant has been shown before to exhibit complete loss of function of MeCP2, 
and no longer repress Sp1-mediated transcriptional activation of methylated and 
unmethylated promoters 9. We found that it mislocalizes to the nucleoli instead of 
pericentric heterochromatin (Figure 2 and Figure S1). Except for P101H, R133H, 
E137G, A140V, all the other analyzed mutant proteins accumulated at 
chromocenters less than the wild type, with more than half significantly affected in 
their accumulation ability as compared to wild type (p value shown in the table, 
Figure 2). 
Since several mutants associated less efficiently with heterochromatin, we then 
tested whether they would be impaired in their ability to cluster heterochromatin in 
vivo. To assess the degree of heterochromatin clustering in a quantitative manner, 
we scored the number of chromocenters in cells expressing the wild type and mutant 
proteins (Figure 3). A statistical analysis was performed utilizing a Kolmogoroff-
Smirnoff test comparing cumulative frequencies of chromocenter numbers. The 
potential of the proteins to induce clustering is reflected by the slope of the 
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cumulative frequency curve, which represents the percentage of nuclei with a certain 
number of chromocenters or less. A steeper curve consequently means a higher 
percentage of nuclei with a lower number of chromocenters. The Kolmogoroff-
Smirnoff test revealed a significantly larger amount of chromocenters in cells 
expressing P101H mutant protein compared to wild type MeCP2 expressing cells. 
This was also the case for the R111G mutant, which though did not at all 
accumulated at heterochromatin. The A140V mutant on the other extreme behaved 
similarly to wild type MeCP2. This mutation has not only been reported in association 
with very mild clinical symptoms 10. Altogether, a third of the mutant proteins were 
significantly affected and showed an intermediate clustering potential as compared to 
wild type. We further tested this effect in human cells expressing wild type or mutant 
MeCP2 by immunostaining in combination with fluorescence in situ hybridization 
using three DNA probes simultaneously to detect the major pericentric 
heterochromatin regions present in chromosomes 1, 9 and 16, and obtained a similar 
outcome (Figure S3A and B).  
Next we tested whether the clustering of chromocenters generally reflected the 
amount of protein that accumulated at these regions. Hence, we plotted the median 
of chromocenter number versus the average accumulation at chromocenters (Figure 
4A). Mutants falling onto an arbitrary line connecting the negative GFP alone control 
and the positive wild type MeCP2 control show an inverse correlation between 
binding to chromocenters and corresponding numbers of chromocenters, i.e. binding 
less is accompanied by more clustering. Interestingly, in the majority of the mutants 
neither a direct nor an inverse correlation between both parameters was found. In 
fact, several mutants were deficient in heterochromatin binding but only mildly 
affected in clustering of chromocenters and grouped to the left of the line (Figure 4A, 
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green) whereas the majority of mutants were mildly to non-affected in 
heterochromatin binding but disproportionately affected in clustering of 
chromocenters and grouped to the right of the line (Figure 4A, red). Interestingly, 
when we applied the same color code to label the residues in the MBD structure, the 
two subclasses nicely segregated onto two different surfaces of this domain (Figure 
4B). The latter indicated that, in addition to the residues known to make contact with 
the methylated cytosines indicated in blue (Figures 1C and 4), this domain could be 
further functionally subdivided into a surface affecting primordially heterochromatin 
association (in green) and a second surface involved in clustering chromatin (in red). 
Mutants in these different MBD subdomains could be predicted to have different 
binding kinetics in vivo. Hence, we performed in situ extraction as well as 
fluorescence photobleaching recovery experiments on selected mutants that were 
either not affected in binding and clustering of chromatin (A140V), or affected only in 
clustering (P101H) or in both functions (R133L). The R133L mutation resulted in 
higher extractability and a much faster FRAP recovery, probably reflecting disruption 
of binding to the methylated cytosines. A minimal level of 5mC seems to be required 
for efficient accumulation of MeCP2 at heterochromatin, as shown by the lack of 
chromocenter localization of a GFP-tagged MBD fusion in Dnmt1/3a/3b triple knock-
out cells 12. Our live-cell kinetic data indeed indicated that albeit the ability to 
accumulate at heterochromatin to a low extent, the R133L mutant MeCP2 interacted 
only very transiently and with low affinity. Very similar FRAP kinetics were recently 
reported for different mutation of this residue, R133C 13. Both substitutions had 
similar heterochromatin clustering potential (Figure 3) although the R133L had a 
somehow lower ability to accumulate at heterochromatin (Figure 2). The in vivo 
accumulation of this mutant at chromatin may be either due to its retaining low affinity 
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recognition of 5mC and/or binding to DNA or other heterochromatin-associated 
proteins. On the other extreme, the A140V mutant protein performed in both assays, 
in situ extraction and FRAP kinetics, as the wild type or even more stably bound to 
chromatin (Figure 5). Importantly, the P101H mutant, which accumulated as the wild 
type at heterochromatin was drastically impaired in clustering chromocenters, and 
had an intermediate FRAP kinetics and was also easier to extract from 
heterochromatin. The FRAP kinetics follow the same trend for the different mutants 
independently of whether the region photobleached included only chromocenters 
(Figure 5B; which measures mostly the contribution of heterochromatin-bound 
MeCP2) or half of the nucleus (Figure 5C; with a higher contribution of the 
nucleoplasmic MeCP2 fraction) or was measured in human cells (Figure S2C). 
Since the P101 is located far away from the 5mC interacting pocket, these data 
suggest that it is primordially involved in connecting chromatin fibers either through 
direct DNA interaction or, more likely, interactions with other chromatin proteins. All 
other substitutions of P101 to L, R, S and T affected heterochromatin clustering albeit 
to different extent. This residue is located in N-terminal part of the MBD and likely 
induces a sharp turn before the two opposing beta-sheets (β1 and β2, Figure 1). 
Interference with this rigid conformation may be more significant upon replacement 
with the not very flexible histidine and less with more malleable amino acids.  
In summary, our analysis of the in vivo chromocenter clustering ability of the different 
mutations clearly indicated that all mutants where this property was significantly 
disrupted (including P101H) mapped to this same surface of the MBD three-
dimensional structure and, importantly, these mutants were not concomitantly 
affected in chromatin binding. Such mutants would be able to bind to DNA quite well, 
as reflected by the chromatin accumulation data, but would be affected in binding to 
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other proteins present at chromatin and, therefore, could not induce chromocenter 
clustering resulting in faster binding dynamics at chromatin. Compared to other 
chromatin binders, the FRAP kinetics of wild type MeCP2 are much faster than the 
core histone components 14 but close to the kinetics of linker histone H1 15,16. Both 
MeCP2 and H1 compete for binding to nucleosomes in vitro 17 and bind to the linker 
DNA 18,19. Moreover, MeCP2 is able to condense chromatin in vitro at the same level 
as histone H1 and under physiological salt concentrations 20. These in vitro data 
suggest that MeCP2 can “crosslink” chromatin fibers together similar linker histone 
H1. We have previously shown that MeCP2 clusters chromatin in vivo 8 and our 
present data suggests that mutations occurring in Rett patients are defective 
precisely in this function. 
Our results and the results from literature 21 on FRAP from other chromatin proteins 
like HP1, show that it is highly mobile with a very fast recovery kinetics (Figure S3). 
The results together point in the direction that proteins that serve/work as chromatin 
compacters, have a stronger binding at the chromatin and thus have a slow recovery 
kinetics. We propose that proteins that lead to higher order chromatin organization 
should not only have a good binding at the chromocenters through multiple modes of 
interactions, but also should stay there for a longer time. This longer residence time 
might help them to make multiple higher order contacts and thus can serve as linkers 
for DNA or chromatin.  
Less stable MeCP2 heterochromatin binding and/or smaller heterochromatin 
domains within the nucleus could conceivably play a role in Rett syndrome etiology. 
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Materials and methods 
Expression plasmids 
Expression vectors encoding GFP-tagged fusions of human wild type or mutant 
MeCP2 cDNA cloned into the pEGFP-C1 vector were described before 9 as was 
GFP-HP1α 21. 
 
Cell culture, transfection and staining 
Pmi28 mouse myoblasts were cultured as described 23. Cells were plated on glass 
coverslips or multiwell dishes (ibidi µ dishes 8 well; Ibidi GmbH, Munich, Germany) 
prior to transfection for fixed cell or live cell experiments, respectively. Cells were 
transfected using TransFectinTM (BioRad, Hercules, CA) following the manufacturer’s 
protocol. Cultures were fixed and DNA stained as described 24. In short, cultures 
were rinsed in PBS and fixed in 3.7% formaldehyde in PBS. Nuclear DNA was 
counterstained using TOPRO-3 (Invitrogen, Carlsbad, CA), Hoechst 33258 or DAPI 
(4’ -6’-diamidino-2-phenylindol) and samples were mounted in vectashield antifading 
medium (Vector Laboratories, Burlingame, CA) or moviol. 
 
Microscopy and image analysis 
Chromocenter clustering induced by GFP-tagged MeCP2 and mutants was assessed 
by visual inspection of GFP and/or DNA signals using widefield epifluorescence 
microscopy with appropriate filter sets (Axiovert 200 microscope; 63x Plan 
apochromat NA1.4 oil lens, Zeiss, Jena) and counting chromocenters in 50-55 nuclei. 
Cumulative frequencies of chromocenter numbers were tested for statistical 
significance differences using a Kolmogoroff-Smirnoff test with Microsoft Excel 
software and plotted with Origin 7.5 software (Origin Lab Corp). 
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To assess the chromocenter binding ability, we collected confocal Z stacks (voxel 
size: 0.05 x 0.05 x 0.3 µm) of 10-15 cells expressing similar levels of the GFP fusion 
protein on either Zeiss LSM510Meta or Leica SP5 microscopes, using 63x/1.4NA oil 
objective and 405nm DPSS (for Hoechst 33258, DAPI), 488nm argon (for GFP) and 
633nm He-Ne (TOPRO-3) laser excitation. Care was taken in selecting the imaging 
conditions to avoid under and over exposed pixels, while keeping the imaging 
conditions constant. The heterochromatic foci were identified by staining with 
TOPRO-3, Hoechst 33258 or DAPI. Image analysis was done using ImageJ version 
1.38x (http://rsb.info.nih.gov/ij). The average mean intensity at the chromocenters 
versus the nucleoplasm was assessed by selecting four regions of equal size in the 
two compartments, calculating the mean fluorescent intensity in each compartment 
and then taking a ratio between both. The formula used to calculate the accumulation 
of MeCP2 and mutants at chromocenters for each construct was: 
Accumulation at chromocenter = average mean intensity at chromocenters / average 
mean intensity in nucleoplasm 
In situ extraction of GFP-tagged wildtype MeCP2, and MeCP2 bearing mutants was 
done by transfecting the cells plated on ibidi dishes with the respective construct. 
Cells were first washed with PBS containing 0.5mM MgCl2, 0.5mM CaCl2 and 
imaged. Then the solution was changed to PBS containing 0.5mM MgCl2, 0.5mM 
CaCl2 and 0.5% Triton X-100. Confocal Z series were recorded over time on a Zeiss 
LSM510Meta microscope, using 63x/1.4NA oil objective. The microscope was 
equipped with a microscope cage incubation chamber (Oko-lab, Ottaviano, Italy) and 
the temperature was maintained at 37oC. GFP was excited with the 488nm argon 
laser line. Confocal Z stacks were acquired with a frame size of 1024 x 1024 pixels 
(voxel size: 0.20 x 0.20 and 1.0µm), at 2 minutes time intervals for 14 minutes. 
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Quantitative evaluation was performed using ImageJ. The mean fluorescence 
intensities at the chromocenters for each cell and time point were calculated for PBS 
and PBS-Triton X-100. First, using ImageJ ‘adjust threshold’ plug-in the 
chromocenters were identified and then ‘create selection’ plug-in was used to assess 
the mean fluorescence intensity only at chromocenters. This procedure was repeated 
for each cell and time point. The whole data set for each cell was then normalized to 
the mean fluorescence intensities of the chromocenters before extraction with Triton 
X-100. The results were evaluated using Microsoft Excel and plotted using Origin 7.5 
software (Origin Lab Corp).  
 
Fluorescence recovery after photobleaching 
Live cell imaging and FRAP experiments were performed on a LSM510Meta confocal 
microscope (Zeiss) using a 63x/1.4NA Plan-Apochromat oil immersion objective. The 
microscope was maintained at 37oC with the help of an Oko-lab cage incubation 
chamber. Confocal image series were recorded with a frame size of 512 x 512 pixels, 
a pixel size of 60 nm, and at 2 sec time intervals. 488nm argon laser line (25 mW) 
was used at 100% transmission to bleach and at 0.05% transmission to record GFP-
tagged fluorophores over time, with the pinhole opened to 3 Airy units. Either a whole 
chromocenter or half of the nucleus was photobleached and 5-10 prebleach and 250-
400 postbleach frames were recorded for each time series. Quantitative evaluation 
was performed using ImageJ and Microsoft Excel. The time series was first corrected 
for translational movements using ‘stackreg’ plug-in from ImageJ and the analysis of 
the FRAP data was performed exactly as described 25. 
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Figures 
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Figure 1: Summary of frequency and localization of MeCP2 Rett mutations. 
(A) Mutation spectrum in Rett patients (IRSA http://mecp2.chw.edu.au/cgi-
bin/mecp2/search/printGraph.cgi#MS), with missense mutations shown in black and 
the others in grey color. Location of individual mutations is indicated on a schematic 
representation of the MeCP2 protein (numbers are amino acids coordinates). MBD 
stands for methyl CpG binding domain, TRD for transcription repression domain and 
NLS for nuclear localization signal. (B) shows a model of the MBD of MeCP2 (yellow) 
interacting with its target 5mC within the DNA double helix 6. Structural data was 
displayed and annotated using PyMOL software (http://pymol.sourceforge.net/). The 
DNA backbone is shown in white along with the methylated cytosines. The MBD of 
MeCP2 is displayed in yellow. The parts of the MBD that make contacts with the 
5mC on DNA are highlighted in blue in the structure on the left hand side and in the 
MeCP2 MBD sequence alignment shown below. (C) The five residues that directly 
interact with the two 5mC are shown in blue. The 21 mutations included in our study 
are listed below the corresponding wild type amino acid on MBD (pink). 
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Figure 2: Mutant MeCP2 proteins accumulate at chromocenters in vivo, albeit 
to very different extent. 
Representative overlay images of phase contrast and GFP fluorescence of cells 
expressing wild type MeCP2 and mutants, showing differential chromocenter 
accumulation ability. The dashed lines indicate the location of the nucleoli. The dot 
plot chart shows the fold accumulation at chromocenters of the 21 mutant proteins, 
the wild type MeCP2 and the EGFP tag alone as controls. All the mutants except 
R111G accumulate at chromocenters, but to very different extent. The yellow color 
highlights the mutants whose accumulation was significantly different (p≤ 0.05) from 
wild type. All mutants accumulated significantly different (p≤ 0.05) with respect to 
EGFP protein alone control (not shown). The table lists the average value of 
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accumulation of each protein at the chromocenters, along with their p value with 
respect to the wild type MeCP2. The experiment was repeated twice with 10-15 cells 
per mutant evaluated each time. 
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Figure 3: Rett mutant proteins are affected in their ability to cluster 
chromocenters. 
(A) The plot shows the percentage cumulative frequencies of chromocenter numbers 
in cells expressing GFP-tagged wild type MeCP2 versus untransfected cells and 
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EGFP transfected cells. (B) Cumulative frequencies of chromocenter numbers in 
cells expressing each of the 21 GFP-tagged MeCP2 mutants. (C) depicts the MeCP2 
Rett mutants that are either most affected (P101H), or less affected (A140V), as well 
as the extreme case of R111G that has lost its ability to bind chromatin, together with 
the controls (wild type MeCP2, EGFP alone and untransfected cells). The table lists 
the median number of chromocenters for each mutant along with the significance 
difference (p≤ 0.05, highlighted in yellow) of mutants with respect to wild type. All 
mutants except P101H and R111G had the median number of chromocenters 
significantly different (p≤ 0.05) with respect to untransfected cells (not shown). The 
experiment was repeated 2 times with 50 cells evaluated per mutant each time. 
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Figure 4: Correlation analysis of chromocenter clustering and accumulation at 
chromatin. 
(A) Accumulation at chromocenters (see Figure 2) and median of chromocenter 
number (see Figure 3) were plotted on the X and Y-axis respectively. The scatter plot 
neither indicates an overall direct nor an inverse correlation. The theoretical line 
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connecting the GFP alone and GFP-MeCP2 delineates the indirect relationship 
between binding to chromatin and chromocenter number (clustering). Mutants 
grouping above the line are color coded in red and the ones grouping below the line 
are in green. Mutants in residues directly interacting with 5mC are shown in blue (see 
Figure 1C). (B) Structure of the MBD (in yellow) of MeCP2 in complex with DNA (in 
white) was displayed as in Figure 1. The residues were given the corresponding color 
as in part A. The location of the green and red residues within the MBD structure 
showed a similar separation in two groups as on the scatter plot.  
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Figure 5: MeCP2 Rett mutant proteins show different kinetics in vivo. 
To assess the mobility and binding kinetics of wild type MeCP2 versus mutants, we 
performed biochemical in situ as well as fluorescence photobleaching recovery 
experiments. (A) In situ extraction kinetics for GFP-tagged proteins was performed by 
permeabilizing the cells on the microscope stage with Triton X-100 and measuring 
the decrease of protein at chromocenters over time. The experiment was repeated 
twice and 7-10 cells were analyzed each time, for each mutant. The line graph shows 
the extraction kinetics of the mutants over time. Error bars represent the standard 
error of mean and representative mid section images are shown on the right. Scale 
bar represents 10µm. (B) FRAP curves of GFP-tagged wild type and mutant MeCP2 
together with representative images before and after photobleaching. For FRAP 
analysis, either a whole chromocenter or half of the nucleus (marked in white) was 
photobleached. For each construct 15-20 cells were averaged and the mean curve 
as well as the standard error of the mean was calculated. Half times of recovery 
shown on the bar histograms were calculated from the mean curves and the error 
bars represent the standard error of mean. 
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Supplemental figures: 
 
Figure S1: MeCP2 mutants differ in their ability to accumulate at 
chromocenters and to induce their clustering.  
Representative confocal microscopy images of Pmi cells expressing GFP fusions to 
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wild type MeCP2 and each of the 21 MeCP2 Rett mutants used in this work. In the 
left panels, the phase contrast image is shown where the nucleus and nucleoli are 
seen. The middle panels depict the GFP fluorescence of a mid optical section and 
the right panels the overlay of both. Chromocenters were additionally visualized by 
counterstaining for DNA (data not shown). The ratio of protein enriched in 
heterochromatin versus nucleoplasm differs strongly between mutants (see also 
Figure 2), as does their ability to cluster the chromocenters (see also Figure 3). 
Furthermore, R111G mutant does not accumulate at chromocenters but rather at 
nucleoli, as can be seen by the overlay with the phase contrast image. 
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Figure S2: MeCP2 induces heterochromatin clustering in human diploid cells.  
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A) Human foreskin diploid fibroblasts (Bj-hTERT) were transfected with a plasmid 
encoding for GFP-tagged human MeCP2, fixed after 12h and immunostained with 
anti-MeCP2 and anti-GFP. The image shows one exemplary field including one 
transfected cell identified by direct GFP fluorescence as well as anti-GFP and anti-
MeCP2 antibodies staining. The second cell was not transfected and hence shows 
no GFP or anti-GFP signals. The lack of any signal with the MeCP2-specific antibody 
in the untransfected cells indicates that Bj-hTERT cells, similarly to Pmi cells, do not 
contain detectable levels of endogenous MeCP2. (B) The top panel depicts an 
ideogram of G-banded human chromosomes 
(www.pathology.washington.edu/galleries/cytogallery/main.php?file=human%20kary
otypes). Chromosomes 1, 9 and 16 contain the largest pericentric heterochromatin 
regions (marked in red), as compared to the other chromosomes, and were, thus, 
selected for our analysis of MeCP2-induced heterochromatin clustering. Cells were 
transfected with constructs coding for GFP-tagged wild type and mutant human 
MeCP2 and clustering of these heterochromatic regions analyzed by simultaneous 
hybridization with three DNA probes from the pericentric heterochromatin DNA of 
these three chromosomes. Cells expressing the GFP-tagged MeCP2 proteins were 
identified by immunostaining with anti-MeCP2 antibody and DNA was counterstained 
with DAPI. Confocal Z stacks of images from the GFP-MeCP2 signal, overall DNA 
signal and DNA FISH probes were then acquired. The three dimensional rendering of 
one such cell is shown where the contour of the nucleus is depicted by the white grid 
and the FISH signals of the three pericentric heterochromatin regions in red. The 
cumulative frequency % of the FISH signals counted in the presence of different 
MeCP2 mutants is shown together with the table listing the average number of 
chromosome signals and their p value with respect to the wild type MeCP2 (p≤ 0.05, 
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highlighted in yellow). Experiments were repeated twice with 30 cells evaluated each 
time per construct. Even with this extremely narrow dynamic range, between 3 and 6 
chromosome signals, a significant difference could be measured in the number of 
FISH signals, which follows the one found in the chromocenter clustering analysis in 
mouse cells. (C) FRAP and the corresponding kinetic data analysis on the MeCP2 
and mutants expressed in human Bj-hTERT cells. Half times of recovery were 
calculated from the mean curves and are shown in the bar chart. The error bars 
represent the standard error of mean. The experiment was repeated twice with 15-20 
cells evaluated each time per construct. 
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Figure S3: Comparison of the heterochromatin binding kinetics of MeCP2 Rett 
mutant proteins and HP1. 
FRAP curves of GFP-tagged wild type MeCP2, mutant MeCP2 and HP1α expressed 
in Pmi cells together with representative images before and after photobleaching of 
chromocenters (marked in white). For each construct 15-20 cells were averaged and 
the mean curve as well as the standard error of the mean was calculated. Half times 
were determined from the mean curves and are shown in the bar chart. The error 
bars represent the standard error of the mean. 
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Supplemental methods: 
Human cell culture and transfection 
The human foreskin fibroblast (Bj-hTERT) cell line (ATCC BJ-5ta) was derived by 
transfection of human foreskin fibroblasts with the pGRN145 hTERT expression 
plasmid and selection of stable immortalized cell clones 1. It is a diploid human cell 
line with a modal chromosome number of 46 that occurred in 90% of the cells 
counted and karyotypically normal X and Y sex chromosomes. 
Human Bj-hTERT fibroblasts were cultured in DMEM medium containing 10% FCS, 
glutamine and gentamicin. Cells were transfected using the Amaxa nucleofactor 
(Amaxa AG, Cologne, Germany) or TransFectinTM (BioRad, Hercules, CA) following 
the manufacturer’s protocols.  
 
ImmunoFISH 
For fluorescence in situ hybridization, the following DNA probes were used: repetitive 
specific human DNA probe pUC 1.77 2 for chromosome 1, alphoid DNA probe 
pMR9A for the centromeric region 9q12 of chromosome 9 and alphoid DNA probe 
pHUR-195 for the centromeric region 16q11.2 of chromosome 16. These DNA 
probes were labeled by standard nick translation with Cy5-dUTP (Amersham, 
Buckinghamshire, UK). The labeled DNA was further purified by ethanol-precipitation 
and the pellet resuspended in hybridization solution (70% formamide, 2xSSC, 10% 
dextran sulfate, pH 7.0). The probes were denatured at 80 °C for 5 minutes.  
For immunoFISH cells were fixed with 4% paraformaldehyde in PBS for 10 minutes 
and permeabilized with 0.25% Triton X-100 in PBS for another 10 minutes. Primary 
(rabbit polyclonal anti-MeCP2) and secondary (anti-rabbit IgG Alexa Fluor 568; 
Molecular probes, CA, USA) antibodies were diluted in PBS with 0.2% fish skin 
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gelatin and incubated sequentially for one hour each at room temperature. After 
immunostaining, the cells are post-fixed with 4% paraformaldehyde for 60 minutes 
followed by post-permeabilization with 0.5% Triton X-100 in PBS for 10 minutes, 0.1 
M HCl for 10 minutes and 20% glycerol for 4 minutes. Probes were added to the cells 
and sealed with rubber cement to decrease evaporation of the probe over night. They 
were then denatured simultaneously at 75 °C for 5 minutes and hybridized over night 
at 37 °C. Non-hybridized probe was washed off using 50% formamide in SSC at 45 
°C three times followed by two washes with 2xSSC. DNA was counterstained with 
DAPI and the cells were mounted using vectashield.  
MeCP2 expressing cells were identified by the positive staining with the anti-MeCP2 
antibody and complete Z stacks of images (voxel size: 80 x 80 x 200 nm) of the DAPI 
(excited at 405 nm) and Cy5 (excited at 633 nm) signals for whole DNA and 
chromosomes 1, 9 and 16 pericentric heterochromatin regions, respectively, were 
acquired on a Leica SP5 laser scanning microscope using a 63x/1.4NA oil objective.  
FISH signals were counted manually through these stacks. 3D rendering was done 
using UCSF chimera (www.cgl.ucsf.edu/chimera).  
 
 
Supplemental references: 
1. Bodnar, A.G. et al. Extension of life-span by introduction of telomerase into normal 
human cells. Science 279, 349-52 (1998). 
2. Cooke, H.J. & Hindley, J. Cloning of human satellite III DNA: different components 
are on different chromosomes. Nucleic Acids Res 6, 3177-97 (1979). 
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4. DISCUSSION 
In recent years, lot of research work has already been done on MeCP2 but still little is 
known about its role in chromatin reorganization during development and disease. In 
this study, using a combination of biochemical and microscopical techniques, I could 
show an interaction and interdependency between two major epigenetic factors, MeCP2 
and HP1. Furthermore, I demonstrate that MeCP2 plays an important role in 
determining higher order chromatin organization and, disruption of this function, takes 
place on MeCP2 mutants found in patients with a neurological disorder termed Rett 
syndrome. 
 
4.1. Chromatin clustering is induced by MeCP2 and not HP1 during differentiation 
Recently, our group has shown that the MBD domain of MeCP2 is capable of causing 
chromosome clustering (Brero et al., 2005). In the present work, I have dissected this 
chromocenter clustering property of MeCP2 in vivo, during differentiation and disease. 
Recently, it has been shown that MeCP2 binds to nucleosomes in a very similar manner 
as linker histone H1 (Ishibashi et al., 2008) and, accordingly, MeCP2 was able to 
displace linker H1 pre-bound to chromatin (Nan et al., 1997). When the chromatin 
compacting properties of MeCP2 are compared with linker histones like H1 and H5, 
MeCP2 appears to have a stronger effect. As shown in vitro (Georgel et al., 2003) and 
in vivo (Brero et al., 2005), MeCP2 forms highly compacted condensed structures, 
whereas linker histones are shown to form a relatively decondensed zigzag 
conformation of nucleosomes and linker DNA (Bednar et al., 1998). In fact, histone H1-
bound chromatin can reach an equivalent amount of compaction to MeCP2-bound 
chromatin but only at three times higher ionic strength (Hansen, 2002).  
We have recently shown that HP1 does not cause chromocenter clustering in vivo 
(Brero et al., 2005). Also, in this work I could show that HP1 alone cannot cause 
chromocenter clustering, and the latter only occurred in cells co-expressing an MBD 
family member (Agarwal et al., 2007). Furthermore, it has been shown that HP1α, does 
not have a similar binding mode to nucleosomal arrays as MeCP2 (Fan et al., 2004). 
MeCP2 has been shown to be capable of folding nucleosomal arrays (Georgel et al., 
2003) in vitro, whereas HP1α can only bind to folded nucleosomal arrays (Fan et al., 
2004). Hence, HP1α per se might only be able to induce local rearrangements of folded 
secondary chromatin structures, and does not seem to be able to cause the formation of 
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such structures themselves. The results of the kinetic FRAP analysis on HP1α versus 
MeCP2 in this work indicated that HP1 is far more mobile on chromatin than MeCP2. 
The latter likely reflects the multiple chromatin binding modes of MeCP2 (Chahrour et 
al., 2008; Cohen et al., 2008), recognizing methylated cytosines as well as DNA, which 
could allow and/or facilitate intra/inter-chromatin fiber connections resulting in clustering 
and compaction of chromatin. 
 
4.2. Chromatin clustering is affected by mutations in MeCP2 
Mutations in MeCP2 gene are found in 80% of Rett syndrome patients (Trappe et al., 
2001).The difference in phenotypic variability associated with different mutations on 
MeCP2 gene depends upon the pattern of X chromosome inactivation (XCI). In females, 
one of the two X chromosomes is active in each cell. This results in a mosaic situation, 
in terms of X chromosome gene expression (either maternal or paternal) and further 
complicates any gene therapy based approach. 
Several reports in the literature point to the fact that missense mutations are mostly 
present on the MBD domain of MeCP2. Since our data showed that this domain is 
necessary and sufficient to cause chromatin clustering (Brero et al., 2005), I 
investigated whether these mutations affected this novel function of MeCP2. To 
determine the significance of these missense mutations on the chromatin compaction 
ability of MeCP2, I examined this effect on a total of 21 MBD missense Rett mutations. 
Through several assays, I could show in the present work that mutations on the MBD 
domain of MeCP2 can indeed result in disruption of distinct functions of MeCP2 like 
accumulation and dynamics of protein at chromocenters, and chromocenter clustering. I 
could also overlay the results from our analysis as a whole on the structure of the MBD 
domain of MeCP2.  
I could show that P101H mutant protein revealed a significantly larger amount of 
chromocenter number as compared to wild type. Also, R111G mutant showed defect in 
chromocenter clustering ability and has been shown earlier to result in a complete loss 
of function of MeCP2 (Kudo et al., 2003) and, indeed, I could not detect any binding to 
heterochromatin. Replacement of proline with histidine at position 101 might result in 
large-scale changes in the protein structure, as proline provides a nick and rigidity at 
that position in the protein structure, whereas histidine being a flexible amino acid might 
prevent it. MeCP2 A140V mutant retained chromatin binding and clustering equivalent 
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to wild type. It has been shown that A140V mutation correlates with an almost normal 
clinical phenotype (Couvert et al., 2001; Orrico et al., 2000) and even males with this 
mutation can survive, being therefore a very mild mutation. 
The analysis of the accumulation of protein at pericentric heterochromatin indicated that 
R106W and R111G, though still able to bind at chromocenters, show the lowest 
accumulation ability. R106W has been shown to lie on the ß2 sheet (Wakefield et al., 
1999) and so has been predicted to strongly impair MBD function and inducing 
misfolding of MBD (Ballestar et al., 2000; Yusufzai and Wolffe, 2000). In addition to 
residue R111, residues R133 and S134 interact directly with the methylated cytosines. I 
tested three mutants of R133 residue, R133H accumulated better than wild type MeCP2, 
R133C accumulated less and R133L was the least able to accumulate, though all the 
three accumulated significantly different from wild type MeCP2. S134C mutant 
accumulated similarly to wild type MeCP2. R133 and S134 have been shown to be less 
critical for the MBD function than R111 (Kudo et al., 2003). K135E, E137G, T158A, 
T158M, Y120D, F155I showed intermediate impairment in chromatin binding.  
To determine whether the MeCP2 MBD mutations affected the kinetics of 
chromatin binding, I performed in vivo kinetic studies (in situ extraction and FRAP) on 
selected mutants, which were either not affected in binding and clustering of chromatin 
(A140V), or affected only in clustering (P101H) or in both functions (R133L). R133L 
mutation resulted in higher extractability and a much faster FRAP recovery. This could 
be explained if we take into consideration the predicted NMR solution structure of 
MeCP2 with methylated DNA (Ohki et al., 2001; Ohki et al., 1999; Wakefield et al., 
1999), indicating that this residue is involved in binding to the methylated cytosines. 
Furthermore, methyl cytosines seem to be required for efficient accumulation of MeCP2 
at heterochromatin, as shown by the lack of chromocenter localization of a GFP-tagged 
MBD fusion in Dnmt1/3a/3b triple knock-out cells (Tsumura et al., 2006). Our live-cell 
kinetic data indeed indicates that albeit able of accumulate at heterochromatin to a low 
extent, the R133L mutant MeCP2 interacts only transiently and with low affinity. The in 
vivo accumulation of this mutant to chromatin may be either due to retaining a low 
affinity recognition of methylcytosine and/or binding to DNA or other heterochromatin-
associated proteins. The results of kinetic data from P101H mutant highlight an 
intermediate ability to bind chromatin, whereas A140V mutant is quite similar to wild 
type MeCP2. In view of the position of the P101 residue in the MBD structure and the 
fact that this domain is not known to bind DNA (Nikitina et al., 2007b), I propose that this 
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surface of the MBD is likely involved in protein-protein interactions promoting 
connections between chromatin. My analysis of the in vivo chromocenter clustering 
ability of the different mutations clearly indicated that all mutants where this property 
was significantly disrupted (including P101H) mapped to this same surface of the MBD 
three-dimensional structure and, importantly, these mutants were not concomitantly 
affected in chromatin binding. Such mutants would be able to bind to DNA quite well, as 
is also clear from the chromatin accumulation data, but would be affected in binding to 
other proteins present at the chromatin and, therefore, could not induce chromocenter 
clustering resulting in faster binding dynamics at chromatin. Less stable MeCP2 
heterochromatin binding and/or smaller heterochromatin domains within the nucleus 
could conceivably play a role in Rett syndrome etiology. 
 
4.3. Modes of MeCP2 binding that lead to higher order chromatin structures 
Based on our results and the results from other groups, I hypothesize that there are at 
least three binding classes for MeCP2: (a) binding to methylated and unmethylated 
chromatin (b) binding to other chromatin proteins (c) binding to itself. 
 
4.3.1. Binding of MeCP2 to methylated or unmethylated chromatin 
There are several lines of evidence in the literature showing the binding of MeCP2 to 
DNA and chromatin. It has been shown that MeCP2 forms discrete complexes with 
nucleosomal DNA associating with methyl-CpGs exposed in the major groove via the 
methyl-CpG-binding domain (MBD). The interaction of MBD domain of MeCP2 to 
methylated DNA is due to the presence of five highly conserved residues that form a 
hydrophobic patch (Ohki et al., 2001). 
Furthermore, in vitro MeCP2 can bind to methylated as well as unmethylated DNA 
(Georgel et al., 2003). In addition to the MBD, the carboxyl-terminal segment of MeCP2 
facilitates binding both to naked DNA and to the nucleosome core (Chandler et al., 
1999).  
 
4.3.2. Binding of MeCP2 to chromatin proteins 
A connection between chromatin structure, DNA methylation and histone acetylation 
has been long known and discussed. MeCP2 could serve as an interconnecting 
element in this phenomenon. Evidence in that direction comes from the fact that, during 
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biochemical purifications of MeCP2, in both mammals and Xenopus, Sin3A was also 
co-purified (Jones et al., 1998; Nan et al., 1998), along with HDAC.  
MeCP2 has been shown to interact in addition with several proteins as shown earlier in 
Figure 6. In this study, I also found a novel interacting partner of MeCP2, HP1 (Agarwal 
et al., 2007) which is involved in transcriptional silencing.  
 
We have recent preliminary evidence indicating homo and heterodimerization between 
MBD protein family members (data not shown).  
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Figure 9. Model depicting different modes of MeCP2 binding and MeCP2 induced higher order 
chromatin structures. 
The model in Figure 9 highlights the different binding modes of MeCP2. Though no 
strict order of binding that can be predicted at this time, binding to methylated DNA 
could constitute a basic initial binding site for MeCP2. This is suggested by the lack of 
DISCUSSION 
 
-81- 
heterochromatin association of the MBD domain of another family member MBD1 in the 
triple knockout ES cells for Dnmt1/a/3b (Tsumura et al., 2006). This basic binding of 
MBD proteins to methylated cytosines could be followed by binding of several other 
proteins to MeCP2 as well as the interaction between MeCP2 itself and other MBD 
protein family members. I suggest that the cooperation of all these binding modes, 
which individually may have low affinity, promotes ultimately stable association of 
MeCP2 at heterochromatin, as measured in the FRAP and in situ extraction 
experiments. This stable binding could facilitate connections within and between 
chromatin fibers and lead to a dynamic yet stable organization of heterochromatin 
domains with a modulating effect on the level of transcriptional noise. 
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5. OUTLOOK 
Building upon the results obtained in this work, several lines of investigation could be 
pursued. 
It would be interesting to elucidate the role of MeCP2, with special emphasis on the 
MBD domain in chromatin compaction in vitro. The goal of the project would be to know 
in detail, which part of the MBD domain is responsible for such an effect. This could be 
done by performing chromatin aggregation assays using recombinant purified MeCP2 
starting with the particular Rett mutants identified in this analysis. 
Another interesting set of parallel experiments would be to screen for interacting 
partners of MeCP2. This could be done in several ways: (a) yeast 2 hybrid approach (b) 
fluorescence 3 hybrid assay (c) mass spec analysis of MeCP2 co-precipitated proteins, 
followed by validation by GST pull down assays. This could be followed by comparing 
the proteins co-precipitating with wild type versus mutant MeCP2 thus would also allow 
to pinpoint which protein interaction(s) are relevant for chromatin clustering. 
During this work, I got several preliminary results indicating that MeCP2 interacts with 
itself and other members of the MBD family. A detailed analysis of these interactions 
should be performed together with a better mapping of the domains involved. In vivo co-
immunoprecipitation as well as in vitro pull-down assays together with deletion analysis 
should be performed as was done for the characterization of the HP1 interaction with 
MeCP2. In addition, the size of the MeCP2 containing complexes could be determined 
by gel filtration analysis of cell extracts as well as in vitro reconstituted complexes. 
Finally, it would be very interesting to elucidate the structure of the mutant proteins 
analyzed in this study, in particular, P101H, R111G, R133L, A140V etc. This, together 
with the identification of binding partners (DNA or proteins) affected by the particular 
Rett mutations, should help elucidating the mechanism of chromatin higher-order 
organization by MeCP2. 
 
 
 
 
 
 
 
REFERENCES 
 
-83- 
6. REFERENCES 
Aasland, R. and Stewart, A.F. (1995) The chromo shadow domain, a second chromo 
domain in heterochromatin-binding protein 1, HP1. Nucleic Acids Res, 23, 3168-
3173. 
Agarwal, N., Hardt, T., Brero, A., Nowak, D., Rothbauer, U., Becker, A., Leonhardt, H. 
and Cardoso, M.C. (2007) MeCP2 interacts with HP1 and modulates its 
heterochromatin association during myogenic differentiation. Nucleic Acids Res, 
35, 5402-5408. 
Ainsztein, A.M., Kandels-Lewis, S.E., Mackay, A.M. and Earnshaw, W.C. (1998) 
INCENP centromere and spindle targeting: identification of essential conserved 
motifs and involvement of heterochromatin protein HP1. J Cell Biol, 143, 1763-
1774. 
Amir, R.E., Van den Veyver, I.B., Wan, M., Tran, C.Q., Francke, U. and Zoghbi, H.Y. 
(1999) Rett syndrome is caused by mutations in X-linked MECP2, encoding 
methyl-CpG-binding protein 2. Nat Genet, 23, 185-188. 
Armstrong, D. (1997) Recent developments in neuropathology--electron microscopy--
brain pathology. Eur Child Adolesc Psychiatry, 6 Suppl 1, 69-70. 
Armstrong, D., Dunn, J.K., Antalffy, B. and Trivedi, R. (1995) Selective dendritic 
alterations in the cortex of Rett syndrome. J Neuropathol Exp Neurol, 54, 195-
201. 
Armstrong, D.D., Dunn, K. and Antalffy, B. (1998) Decreased dendritic branching in 
frontal, motor and limbic cortex in Rett syndrome compared with trisomy 21. J 
Neuropathol Exp Neurol, 57, 1013-1017. 
Bachman, K.E., Rountree, M.R. and Baylin, S.B. (2001) Dnmt3a and Dnmt3b are 
transcriptional repressors that exhibit unique localization properties to 
heterochromatin. J Biol Chem, 276, 32282-32287. 
REFERENCES 
 
-84- 
Bailis, J.M., Bernard, P., Antonelli, R., Allshire, R.C. and Forsburg, S.L. (2003) Hsk1-
Dfp1 is required for heterochromatin-mediated cohesion at centromeres. Nat Cell 
Biol, 5, 1111-1116. 
Ballestar, E., Yusufzai, T.M. and Wolffe, A.P. (2000) Effects of Rett syndrome mutations 
of the methyl-CpG binding domain of the transcriptional repressor MeCP2 on 
selectivity for association with methylated DNA. Biochemistry, 39, 7100-7106. 
Bannister, A.J., Zegerman, P., Partridge, J.F., Miska, E.A., Thomas, J.O., Allshire, R.C. 
and Kouzarides, T. (2001) Selective recognition of methylated lysine 9 on histone 
H3 by the HP1 chromo domain. Nature, 410, 120-124. 
Bednar, J., Horowitz, R.A., Grigoryev, S.A., Carruthers, L.M., Hansen, J.C., Koster, A.J. 
and Woodcock, C.L. (1998) Nucleosomes, linker DNA, and linker histone form a 
unique structural motif that directs the higher-order folding and compaction of 
chromatin. Proc Natl Acad Sci U S A, 95, 14173-14178. 
Bhattacharya, S.K., Ramchandani, S., Cervoni, N. and Szyf, M. (1999) A mammalian 
protein with specific demethylase activity for mCpG DNA. Nature, 397, 579-583. 
Bhaumik, S.R., Smith, E. and Shilatifard, A. (2007) Covalent modifications of histones 
during development and disease pathogenesis. Nat Struct Mol Biol, 14, 1008-
1016. 
Bienvenu, T., Carrie, A., de Roux, N., Vinet, M.C., Jonveaux, P., Couvert, P., Villard, L., 
Arzimanoglou, A., Beldjord, C., Fontes, M., Tardieu, M. and Chelly, J. (2000) 
MECP2 mutations account for most cases of typical forms of Rett syndrome. 
Hum Mol Genet, 9, 1377-1384. 
Brasher, S.V., Smith, B.O., Fogh, R.H., Nietlispach, D., Thiru, A., Nielsen, P.R., 
Broadhurst, R.W., Ball, L.J., Murzina, N.V. and Laue, E.D. (2000) The structure 
of mouse HP1 suggests a unique mode of single peptide recognition by the 
shadow chromo domain dimer. Embo J, 19, 1587-1597. 
REFERENCES 
 
-85- 
Braunschweig, D., Simcox, T., Samaco, R.C. and LaSalle, J.M. (2004) X-Chromosome 
inactivation ratios affect wild-type MeCP2 expression within mosaic Rett 
syndrome and Mecp2-/+ mouse brain. Hum Mol Genet, 13, 1275-1286. 
Brero, A., Easwaran, H.P., Nowak, D., Grunewald, I., Cremer, T., Leonhardt, H. and 
Cardoso, M.C. (2005) Methyl CpG-binding proteins induce large-scale chromatin 
reorganization during terminal differentiation. J Cell Biol, 169, 733-743. 
Buyse, I.M., Fang, P., Hoon, K.T., Amir, R.E., Zoghbi, H.Y. and Roa, B.B. (2000) 
Diagnostic testing for Rett syndrome by DHPLC and direct sequencing analysis 
of the MECP2 gene: identification of several novel mutations and polymorphisms. 
Am J Hum Genet, 67, 1428-1436. 
Chahrour, M., Jung, S.Y., Shaw, C., Zhou, X., Wong, S.T., Qin, J. and Zoghbi, H.Y. 
(2008) MeCP2, a key contributor to neurological disease, activates and 
represses transcription. Science, 320, 1224-1229. 
Chaillet, J.R., Vogt, T.F., Beier, D.R. and Leder, P. (1991) Parental-specific methylation 
of an imprinted transgene is established during gametogenesis and progressively 
changes during embryogenesis. Cell, 66, 77-83. 
Chandler, S.P., Guschin, D., Landsberger, N. and Wolffe, A.P. (1999) The methyl-CpG 
binding transcriptional repressor MeCP2 stably associates with nucleosomal 
DNA. Biochemistry, 38, 7008-7018. 
Cheadle, J.P., Gill, H., Fleming, N., Maynard, J., Kerr, A., Leonard, H., Krawczak, M., 
Cooper, D.N., Lynch, S., Thomas, N., Hughes, H., Hulten, M., Ravine, D., 
Sampson, J.R. and Clarke, A. (2000) Long-read sequence analysis of the 
MECP2 gene in Rett syndrome patients: correlation of disease severity with 
mutation type and location. Hum Mol Genet, 9, 1119-1129. 
Chen, R.Z., Akbarian, S., Tudor, M. and Jaenisch, R. (2001) Deficiency of methyl-CpG 
binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat 
Genet, 27, 327-331. 
REFERENCES 
 
-86- 
Cheng, X. and Blumenthal, R.M. (2008) Mammalian DNA methyltransferases: a 
structural perspective. Structure, 16, 341-350. 
Cheutin, T., McNairn, A.J., Jenuwein, T., Gilbert, D.M., Singh, P.B. and Misteli, T. 
(2003) Maintenance of stable heterochromatin domains by dynamic HP1 binding. 
Science, 299, 721-725. 
Cohen, S., Zhou, Z. and Greenberg, M.E. (2008) Medicine. Activating a repressor. 
Science, 320, 1172-1173. 
Collins, A.L., Levenson, J.M., Vilaythong, A.P., Richman, R., Armstrong, D.L., Noebels, 
J.L., David Sweatt, J. and Zoghbi, H.Y. (2004) Mild overexpression of MeCP2 
causes a progressive neurological disorder in mice. Hum Mol Genet, 13, 2679-
2689. 
Cook, P.R. (2001) Principles of Nuclear Structure and Function. New York, Wiley-Liss. 
Couvert, P., Bienvenu, T., Aquaviva, C., Poirier, K., Moraine, C., Gendrot, C., Verloes, 
A., Andres, C., Le Fevre, A.C., Souville, I., Steffann, J., des Portes, V., Ropers, 
H.H., Yntema, H.G., Fryns, J.P., Briault, S., Chelly, J. and Cherif, B. (2001) 
MECP2 is highly mutated in X-linked mental retardation. Hum Mol Genet, 10, 
941-946. 
Coy, J.F., Sedlacek, Z., Bachner, D., Delius, H. and Poustka, A. (1999) A complex 
pattern of evolutionary conservation and alternative polyadenylation within the 
long 3"-untranslated region of the methyl-CpG-binding protein 2 gene (MeCP2) 
suggests a regulatory role in gene expression. Hum Mol Genet, 8, 1253-1262. 
Cross, S.H., Meehan, R.R., Nan, X. and Bird, A. (1997) A component of the 
transcriptional repressor MeCP1 shares a motif with DNA methyltransferase and 
HRX proteins. Nat Genet, 16, 256-259. 
D'Esposito, M., Quaderi, N.A., Ciccodicola, A., Bruni, P., Esposito, T., D'Urso, M. and 
Brown, S.D. (1996) Isolation, physical mapping, and northern analysis of the X-
REFERENCES 
 
-87- 
linked human gene encoding methyl CpG-binding protein, MECP2. Mamm 
Genome, 7, 533-535. 
Dragich, J., Houwink-Manville, I. and Schanen, C. (2000) Rett syndrome: a surprising 
result of mutation in MECP2. Hum Mol Genet, 9, 2365-2375. 
Ellison, K.A., Fill, C.P., Terwilliger, J., DeGennaro, L.J., Martin-Gallardo, A., Anvret, M., 
Percy, A.K., Ott, J. and Zoghbi, H. (1992) Examination of X chromosome 
markers in Rett syndrome: exclusion mapping with a novel variation on 
multilocus linkage analysis. Am J Hum Genet, 50, 278-287. 
Fan, J.Y., Rangasamy, D., Luger, K. and Tremethick, D.J. (2004) H2A.Z alters the 
nucleosome surface to promote HP1alpha-mediated chromatin fiber folding. Mol 
Cell, 16, 655-661. 
Flemming, W. (1882) Zellsubstanz, Kern and Zelltheilung, Leipzig. 
Fujita, N., Takebayashi, S., Okumura, K., Kudo, S., Chiba, T., Saya, H. and Nakao, M. 
(1999) Methylation-mediated transcriptional silencing in euchromatin by methyl-
CpG binding protein MBD1 isoforms. Mol Cell Biol, 19, 6415-6426. 
Georgel, P.T., Horowitz-Scherer, R.A., Adkins, N., Woodcock, C.L., Wade, P.A. and 
Hansen, J.C. (2003) Chromatin compaction by human MeCP2. Assembly of 
novel secondary chromatin structures in the absence of DNA methylation. J Biol 
Chem, 278, 32181-32188. 
Goll, M.G., Kirpekar, F., Maggert, K.A., Yoder, J.A., Hsieh, C.L., Zhang, X., Golic, K.G., 
Jacobsen, S.E. and Bestor, T.H. (2006) Methylation of tRNAAsp by the DNA 
methyltransferase homolog Dnmt2. Science, 311, 395-398. 
Gomperts, M., Garcia-Castro, M., Wylie, C. and Heasman, J. (1994) Interactions 
between primordial germ cells play a role in their migration in mouse embryos. 
Development, 120, 135-141. 
REFERENCES 
 
-88- 
Groudine, M. and Conkin, K.F. (1985) Chromatin structure and de novo methylation of 
sperm DNA: implications for activation of the paternal genome. Science, 228, 
1061-1068. 
Guy, J., Gan, J., Selfridge, J., Cobb, S. and Bird, A. (2007) Reversal of neurological 
defects in a mouse model of Rett syndrome. Science, 315, 1143-1147. 
Guy, J., Hendrich, B., Holmes, M., Martin, J.E. and Bird, A. (2001) A mouse Mecp2-null 
mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet, 
27, 322-326. 
Hansen, J.C. (2002) Conformational dynamics of the chromatin fiber in solution: 
determinants, mechanisms, and functions. Annu Rev Biophys Biomol Struct, 31, 
361-392. 
Heitz, E. (1928) Das Heterochromatin der Moose. I. Jahrb. Wiss. Botanik, 69, 762-818. 
Hendrich, B. and Bird, A. (1998) Identification and characterization of a family of 
mammalian methyl-CpG binding proteins. Mol Cell Biol, 18, 6538-6547. 
Hendrich, B., Guy, J., Ramsahoye, B., Wilson, V.A. and Bird, A. (2001) Closely related 
proteins MBD2 and MBD3 play distinctive but interacting roles in mouse 
development. Genes Dev, 15, 710-723. 
Hendrich, B., Hardeland, U., Ng, H.H., Jiricny, J. and Bird, A. (1999) The thymine 
glycosylase MBD4 can bind to the product of deamination at methylated CpG 
sites. Nature, 401, 301-304. 
Hendrich, B. and Tweedie, S. (2003) The methyl-CpG binding domain and the evolving 
role of DNA methylation in animals. Trends Genet, 19, 269-277. 
Ho, K.L., McNae, I.W., Schmiedeberg, L., Klose, R.J., Bird, A.P. and Walkinshaw, M.D. 
(2008) MeCP2 binding to DNA depends upon hydration at methyl-CpG. Mol Cell, 
29, 525-531. 
REFERENCES 
 
-89- 
Horn, P.J. and Peterson, C.L. (2002) Molecular biology. Chromatin higher order folding-
-wrapping up transcription. Science, 297, 1824-1827. 
Horsley, D., Hutchings, A., Butcher, G.W. and Singh, P.B. (1996) M32, a murine 
homologue of Drosophila heterochromatin protein 1 (HP1), localises to 
euchromatin within interphase nuclei and is largely excluded from constitutive 
heterochromatin. Cytogenet Cell Genet, 73, 308-311. 
Huisinga, K.L., Brower-Toland, B. and Elgin, S.C. (2006) The contradictory definitions of 
heterochromatin: transcription and silencing. Chromosoma, 115, 110-122. 
Huppke, P., Laccone, F., Kramer, N., Engel, W. and Hanefeld, F. (2000) Rett syndrome: 
analysis of MECP2 and clinical characterization of 31 patients. Hum Mol Genet, 9, 
1369-1375. 
Ishibashi, T., Thambirajah, A.A. and Ausio, J. (2008) MeCP2 preferentially binds to 
methylated linker DNA in the absence of the terminal tail of histone H3 and 
independently of histone acetylation. FEBS Lett, 582, 1157-1162. 
James, T.C. and Elgin, S.C. (1986) Identification of a nonhistone chromosomal protein 
associated with heterochromatin in Drosophila melanogaster and its gene. Mol 
Cell Biol, 6, 3862-3872. 
Jones, P.L., Veenstra, G.J., Wade, P.A., Vermaak, D., Kass, S.U., Landsberger, N., 
Strouboulis, J. and Wolffe, A.P. (1998) Methylated DNA and MeCP2 recruit 
histone deacetylase to repress transcription. Nat Genet, 19, 187-191. 
Jorgensen, H.F., Ben-Porath, I. and Bird, A.P. (2004) Mbd1 is recruited to both 
methylated and nonmethylated CpGs via distinct DNA binding domains. Mol Cell 
Biol, 24, 3387-3395. 
Jugloff, D.G., Vandamme, K., Logan, R., Visanji, N.P., Brotchie, J.M. and Eubanks, J.H. 
(2008) Targeted delivery of an Mecp2 transgene to forebrain neurons improves 
the behavior of female Mecp2-deficient mice. Hum Mol Genet, 17, 1386-1396. 
REFERENCES 
 
-90- 
Kafri, T., Ariel, M., Brandeis, M., Shemer, R., Urven, L., McCarrey, J., Cedar, H. and 
Razin, A. (1992) Developmental pattern of gene-specific DNA methylation in the 
mouse embryo and germ line. Genes Dev, 6, 705-714. 
Kishi, N. and Macklis, J.D. (2004) MECP2 is progressively expressed in post-migratory 
neurons and is involved in neuronal maturation rather than cell fate decisions. 
Mol Cell Neurosci, 27, 306-321. 
Klose, R.J., Sarraf, S.A., Schmiedeberg, L., McDermott, S.M., Stancheva, I. and Bird, 
A.P. (2005) DNA binding selectivity of MeCP2 due to a requirement for A/T 
sequences adjacent to methyl-CpG. Mol Cell, 19, 667-678. 
Koike, N., Maita, H., Taira, T., Ariga, H. and Iguchi-Ariga, S.M. (2000) Identification of 
heterochromatin protein 1 (HP1) as a phosphorylation target by Pim-1 kinase and 
the effect of phosphorylation on the transcriptional repression function of HP1(1). 
FEBS Lett, 467, 17-21. 
Kourmouli, N., Dialynas, G., Petraki, C., Pyrpasopoulou, A., Singh, P.B., Georgatos, 
S.D. and Theodoropoulos, P.A. (2001) Binding of heterochromatin protein 1 to 
the nuclear envelope is regulated by a soluble form of tubulin. J Biol Chem, 276, 
13007-13014. 
Kriaucionis, S. and Bird, A. (2003) DNA methylation and Rett syndrome. Hum Mol 
Genet, 12 Spec No 2, R221-227. 
Kudo, S., Nomura, Y., Segawa, M., Fujita, N., Nakao, M., Schanen, C. and Tamura, M. 
(2003) Heterogeneity in residual function of MeCP2 carrying missense mutations 
in the methyl CpG binding domain. J Med Genet, 40, 487-493. 
Lachner, M., O'Sullivan, R.J. and Jenuwein, T. (2003) An epigenetic road map for 
histone lysine methylation. J Cell Sci, 116, 2117-2124. 
Lewis, J.D., Meehan, R.R., Henzel, W.J., Maurer-Fogy, I., Jeppesen, P., Klein, F. and 
Bird, A. (1992) Purification, sequence, and cellular localization of a novel 
chromosomal protein that binds to methylated DNA. Cell, 69, 905-914. 
REFERENCES 
 
-91- 
Li, E., Bestor, T.H. and Jaenisch, R. (1992) Targeted mutation of the DNA 
methyltransferase gene results in embryonic lethality. Cell, 69, 915-926. 
Macleod, D., Clark, V.H. and Bird, A. (1999) Absence of genome-wide changes in DNA 
methylation during development of the zebrafish. Nat Genet, 23, 139-140. 
Mann, M.R., Chung, Y.G., Nolen, L.D., Verona, R.I., Latham, K.E. and Bartolomei, M.S. 
(2003) Disruption of imprinted gene methylation and expression in cloned 
preimplantation stage mouse embryos. Biol Reprod, 69, 902-914. 
Matarazzo, V. and Ronnett, G.V. (2004) Temporal and regional differences in the 
olfactory proteome as a consequence of MeCP2 deficiency. Proc Natl Acad Sci 
U S A, 101, 7763-7768. 
McDowell, T.L., Gibbons, R.J., Sutherland, H., O'Rourke, D.M., Bickmore, W.A., Pombo, 
A., Turley, H., Gatter, K., Picketts, D.J., Buckle, V.J., Chapman, L., Rhodes, D. 
and Higgs, D.R. (1999) Localization of a putative transcriptional regulator (ATRX) 
at pericentromeric heterochromatin and the short arms of acrocentric 
chromosomes. Proc Natl Acad Sci U S A, 96, 13983-13988. 
McGill, B.E., Bundle, S.F., Yaylaoglu, M.B., Carson, J.P., Thaller, C. and Zoghbi, H.Y. 
(2006) Enhanced anxiety and stress-induced corticosterone release are 
associated with increased Crh expression in a mouse model of Rett syndrome. 
Proc Natl Acad Sci U S A, 103, 18267-18272. 
Meehan, R.R., Lewis, J.D., McKay, S., Kleiner, E.L. and Bird, A.P. (1989) Identification 
of a mammalian protein that binds specifically to DNA containing methylated 
CpGs. Cell, 58, 499-507. 
Melcher, M., Schmid, M., Aagaard, L., Selenko, P., Laible, G. and Jenuwein, T. (2000) 
Structure-function analysis of SUV39H1 reveals a dominant role in 
heterochromatin organization, chromosome segregation, and mitotic progression. 
Mol Cell Biol, 20, 3728-3741. 
REFERENCES 
 
-92- 
Millar, C.B., Guy, J., Sansom, O.J., Selfridge, J., MacDougall, E., Hendrich, B., 
Keightley, P.D., Bishop, S.M., Clarke, A.R. and Bird, A. (2002) Enhanced CpG 
mutability and tumorigenesis in MBD4-deficient mice. Science, 297, 403-405. 
Minc, E., Allory, Y., Worman, H.J., Courvalin, J.C. and Buendia, B. (1999) Localization 
and phosphorylation of HP1 proteins during the cell cycle in mammalian cells. 
Chromosoma, 108, 220-234. 
Mnatzakanian, G.N., Lohi, H., Munteanu, I., Alfred, S.E., Yamada, T., MacLeod, P.J., 
Jones, J.R., Scherer, S.W., Schanen, N.C., Friez, M.J., Vincent, J.B. and 
Minassian, B.A. (2004) A previously unidentified MECP2 open reading frame 
defines a new protein isoform relevant to Rett syndrome. Nat Genet, 36, 339-341. 
Monk, M., Boubelik, M. and Lehnert, S. (1987) Temporal and regional changes in DNA 
methylation in the embryonic, extraembryonic and germ cell lineages during 
mouse embryo development. Development, 99, 371-382. 
Monros, E., Armstrong, J., Aibar, E., Poo, P., Canos, I. and Pineda, M. (2001) Rett 
syndrome in Spain: mutation analysis and clinical correlations. Brain Dev, 23 
Suppl 1, S251-253. 
Moretti, P., Bouwknecht, J.A., Teague, R., Paylor, R. and Zoghbi, H.Y. (2005) 
Abnormalities of social interactions and home-cage behavior in a mouse model 
of Rett syndrome. Hum Mol Genet, 14, 205-220. 
Muchardt, C., Guilleme, M., Seeler, J.S., Trouche, D., Dejean, A. and Yaniv, M. (2002) 
Coordinated methyl and RNA binding is required for heterochromatin localization 
of mammalian HP1alpha. EMBO Rep, 3, 975-981. 
Murzina, N., Verreault, A., Laue, E. and Stillman, B. (1999) Heterochromatin dynamics 
in mouse cells: interaction between chromatin assembly factor 1 and HP1 
proteins. Mol Cell, 4, 529-540. 
Nan, X., Campoy, F.J. and Bird, A. (1997) MeCP2 is a transcriptional repressor with 
abundant binding sites in genomic chromatin. Cell, 88, 471-481. 
REFERENCES 
 
-93- 
Nan, X., Cross, S. and Bird, A. (1998) Gene silencing by methyl-CpG-binding proteins. 
Novartis Found Symp, 214, 6-16; discussion 16-21, 46-50. 
Nan, X., Meehan, R.R. and Bird, A. (1993) Dissection of the methyl-CpG binding 
domain from the chromosomal protein MeCP2. Nucleic Acids Res, 21, 4886-
4892. 
Ng, H.H., Jeppesen, P. and Bird, A. (2000) Active repression of methylated genes by 
the chromosomal protein MBD1. Mol Cell Biol, 20, 1394-1406. 
Nielsen, A.L., Ortiz, J.A., You, J., Oulad-Abdelghani, M., Khechumian, R., Gansmuller, 
A., Chambon, P. and Losson, R. (1999) Interaction with members of the 
heterochromatin protein 1 (HP1) family and histone deacetylation are 
differentially involved in transcriptional silencing by members of the TIF1 family. 
Embo J, 18, 6385-6395. 
Nielsen, A.L., Sanchez, C., Ichinose, H., Cervino, M., Lerouge, T., Chambon, P. and 
Losson, R. (2002) Selective interaction between the chromatin-remodeling factor 
BRG1 and the heterochromatin-associated protein HP1alpha. Embo J, 21, 5797-
5806. 
Nielsen, S.J., Schneider, R., Bauer, U.M., Bannister, A.J., Morrison, A., O'Carroll, D., 
Firestein, R., Cleary, M., Jenuwein, T., Herrera, R.E. and Kouzarides, T. (2001) 
Rb targets histone H3 methylation and HP1 to promoters. Nature, 412, 561-565. 
Nikitina, T., Ghosh, R.P., Horowitz-Scherer, R.A., Hansen, J.C., Grigoryev, S.A. and 
Woodcock, C.L. (2007a) MeCP2-chromatin interactions include the formation of 
chromatosome-like structures and are altered in mutations causing Rett 
syndrome. J Biol Chem, 282, 28237-28245. 
Nikitina, T., Shi, X., Ghosh, R.P., Horowitz-Scherer, R.A., Hansen, J.C. and Woodcock, 
C.L. (2007b) Multiple modes of interaction between the methylated DNA binding 
protein MeCP2 and chromatin. Mol Cell Biol, 27, 864-877. 
REFERENCES 
 
-94- 
Nonaka, N., Kitajima, T., Yokobayashi, S., Xiao, G., Yamamoto, M., Grewal, S.I. and 
Watanabe, Y. (2002) Recruitment of cohesin to heterochromatic regions by 
Swi6/HP1 in fission yeast. Nat Cell Biol, 4, 89-93. 
Ohki, I., Shimotake, N., Fujita, N., Jee, J., Ikegami, T., Nakao, M. and Shirakawa, M. 
(2001) Solution structure of the methyl-CpG binding domain of human MBD1 in 
complex with methylated DNA. Cell, 105, 487-497. 
Ohki, I., Shimotake, N., Fujita, N., Nakao, M. and Shirakawa, M. (1999) Solution 
structure of the methyl-CpG-binding domain of the methylation-dependent 
transcriptional repressor MBD1. Embo J, 18, 6653-6661. 
Okano, M., Takebayashi, S., Okumura, K. and Li, E. (1999) Assignment of cytosine-5 
DNA methyltransferases Dnmt3a and Dnmt3b to mouse chromosome bands 
12A2-A3 and 2H1 by in situ hybridization. Cytogenet Cell Genet, 86, 333-334. 
Okano, M., Xie, S. and Li, E. (1998) Dnmt2 is not required for de novo and maintenance 
methylation of viral DNA in embryonic stem cells. Nucleic Acids Res, 26, 2536-
2540. 
Olins, A.L. and Olins, D.E. (1974) Spheroid chromatin units (v bodies). Science, 183, 
330-332. 
Olins, D.E. and Olins, A.L. (2003) Chromatin history: our view from the bridge. Nat Rev 
Mol Cell Biol, 4, 809-814. 
Orrico, A., Lam, C., Galli, L., Dotti, M.T., Hayek, G., Tong, S.F., Poon, P.M., Zappella, 
M., Federico, A. and Sorrentino, V. (2000) MECP2 mutation in male patients with 
non-specific X-linked mental retardation. FEBS Lett, 481, 285-288. 
Pak, D.T., Pflumm, M., Chesnokov, I., Huang, D.W., Kellum, R., Marr, J., Romanowski, 
P. and Botchan, M.R. (1997) Association of the origin recognition complex with 
heterochromatin and HP1 in higher eukaryotes. Cell, 91, 311-323. 
REFERENCES 
 
-95- 
Peters, A.H., Kubicek, S., Mechtler, K., O'Sullivan, R.J., Derijck, A.A., Perez-Burgos, L., 
Kohlmaier, A., Opravil, S., Tachibana, M., Shinkai, Y., Martens, J.H. and 
Jenuwein, T. (2003) Partitioning and plasticity of repressive histone methylation 
states in mammalian chromatin. Mol Cell, 12, 1577-1589. 
Polioudaki, H., Kourmouli, N., Drosou, V., Bakou, A., Theodoropoulos, P.A., Singh, P.B., 
Giannakouros, T. and Georgatos, S.D. (2001) Histones H3/H4 form a tight 
complex with the inner nuclear membrane protein LBR and heterochromatin 
protein 1. EMBO Rep, 2, 920-925. 
Rai, K., Chidester, S., Zavala, C.V., Manos, E.J., James, S.R., Karpf, A.R., Jones, D.A. 
and Cairns, B.R. (2007) Dnmt2 functions in the cytoplasm to promote liver, brain, 
and retina development in zebrafish. Genes Dev, 21, 261-266. 
Razin, A. and Szyf, M. (1984) DNA methylation patterns. Formation and function. 
Biochim Biophys Acta, 782, 331-342. 
Reichwald, K., Thiesen, J., Wiehe, T., Weitzel, J., Poustka, W.A., Rosenthal, A., Platzer, 
M., Stratling, W.H. and Kioschis, P. (2000) Comparative sequence analysis of the 
MECP2-locus in human and mouse reveals new transcribed regions. Mamm 
Genome, 11, 182-190. 
Reik, W. and Walter, J. (2001) Evolution of imprinting mechanisms: the battle of the 
sexes begins in the zygote. Nat Genet, 27, 255-256. 
Saito, M. and Ishikawa, F. (2002) The mCpG-binding domain of human MBD3 does not 
bind to mCpG but interacts with NuRD/Mi2 components HDAC1 and MTA2. J 
Biol Chem, 277, 35434-35439. 
Sanford, J.P., Clark, H.J., Chapman, V.M. and Rossant, J. (1987) Differences in DNA 
methylation during oogenesis and spermatogenesis and their persistence during 
early embryogenesis in the mouse. Genes Dev, 1, 1039-1046. 
Scholzen, T., Endl, E., Wohlenberg, C., van der Sar, S., Cowell, I.G., Gerdes, J. and 
Singh, P.B. (2002) The Ki-67 protein interacts with members of the 
REFERENCES 
 
-96- 
heterochromatin protein 1 (HP1) family: a potential role in the regulation of 
higher-order chromatin structure. J Pathol, 196, 135-144. 
Seeler, J.S., Marchio, A., Sitterlin, D., Transy, C. and Dejean, A. (1998) Interaction of 
SP100 with HP1 proteins: a link between the promyelocytic leukemia-associated 
nuclear bodies and the chromatin compartment. Proc Natl Acad Sci U S A, 95, 
7316-7321. 
Shahbazian, M., Young, J., Yuva-Paylor, L., Spencer, C., Antalffy, B., Noebels, J., 
Armstrong, D., Paylor, R. and Zoghbi, H. (2002) Mice with truncated MeCP2 
recapitulate many Rett syndrome features and display hyperacetylation of 
histone H3. Neuron, 35, 243-254. 
Shahbazian, M.D. and Zoghbi, H.Y. (2002) Rett syndrome and MeCP2: linking 
epigenetics and neuronal function. Am J Hum Genet, 71, 1259-1272. 
Sirianni, N., Naidu, S., Pereira, J., Pillotto, R.F. and Hoffman, E.P. (1998) Rett 
syndrome: confirmation of X-linked dominant inheritance, and localization of the 
gene to Xq28. Am J Hum Genet, 63, 1552-1558. 
Song, K., Jung, Y., Jung, D. and Lee, I. (2001) Human Ku70 interacts with 
heterochromatin protein 1alpha. J Biol Chem, 276, 8321-8327. 
Srinivasan, P.R. and Borek, E. (1964) Enzymatic Alteration of Nucleic Acid Structure. 
Science, 145, 548-553. 
Stallcup, M.R. (2001) Role of protein methylation in chromatin remodeling and 
transcriptional regulation. Oncogene, 20, 3014-3020. 
Stancheva, I. and Meehan, R.R. (2000) Transient depletion of xDnmt1 leads to 
premature gene activation in Xenopus embryos. Genes Dev, 14, 313-327. 
Strahl, B.D. and Allis, C.D. (2000) The language of covalent histone modifications. 
Nature, 403, 41-45. 
REFERENCES 
 
-97- 
Tachibana, M., Sugimoto, K., Fukushima, T. and Shinkai, Y. (2001) Set domain-
containing protein, G9a, is a novel lysine-preferring mammalian histone 
methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of 
histone H3. J Biol Chem, 276, 25309-25317. 
Tate, P., Skarnes, W. and Bird, A. (1996) The methyl-CpG binding protein MeCP2 is 
essential for embryonic development in the mouse. Nat Genet, 12, 205-208. 
Thomas, G.H. (1996) High male:female ratio of germ-line mutations: an alternative 
explanation for postulated gestational lethality in males in X-linked dominant 
disorders. Am J Hum Genet, 58, 1364-1368. 
Trappe, R., Laccone, F., Cobilanschi, J., Meins, M., Huppke, P., Hanefeld, F. and Engel, 
W. (2001) MECP2 mutations in sporadic cases of Rett syndrome are almost 
exclusively of paternal origin. Am J Hum Genet, 68, 1093-1101. 
Tsumura, A., Hayakawa, T., Kumaki, Y., Takebayashi, S., Sakaue, M., Matsuoka, C., 
Shimotohno, K., Ishikawa, F., Li, E., Ueda, H.R., Nakayama, J. and Okano, M. 
(2006) Maintenance of self-renewal ability of mouse embryonic stem cells in the 
absence of DNA methyltransferases Dnmt1, Dnmt3a and Dnmt3b. Genes Cells, 
11, 805-814. 
Vassallo, M.F. and Tanese, N. (2002) Isoform-specific interaction of HP1 with human 
TAFII130. Proc Natl Acad Sci U S A, 99, 5919-5924. 
Wade, P.A., Gegonne, A., Jones, P.L., Ballestar, E., Aubry, F. and Wolffe, A.P. (1999) 
Mi-2 complex couples DNA methylation to chromatin remodelling and histone 
deacetylation. Nat Genet, 23, 62-66. 
Wakefield, R.I., Smith, B.O., Nan, X., Free, A., Soteriou, A., Uhrin, D., Bird, A.P. and 
Barlow, P.N. (1999) The solution structure of the domain from MeCP2 that binds 
to methylated DNA. J Mol Biol, 291, 1055-1065. 
Wong, E., Yang, K., Kuraguchi, M., Werling, U., Avdievich, E., Fan, K., Fazzari, M., Jin, 
B., Brown, A.M., Lipkin, M. and Edelmann, W. (2002) Mbd4 inactivation 
REFERENCES 
 
-98- 
increases Cright-arrowT transition mutations and promotes gastrointestinal tumor 
formation. Proc Natl Acad Sci U S A, 99, 14937-14942. 
Wu, C. and Morris, J.R. (2001) Genes, genetics, and epigenetics: a correspondence. 
Science, 293, 1103-1105. 
Xiang, F., Buervenich, S., Nicolao, P., Bailey, M.E., Zhang, Z. and Anvret, M. (2000) 
Mutation screening in Rett syndrome patients. J Med Genet, 37, 250-255. 
Yamamoto, K., Sonoda, M., Inokuchi, J., Shirasawa, S. and Sasazuki, T. (2004) 
Polycomb group suppressor of zeste 12 links heterochromatin protein 1alpha and 
enhancer of zeste 2. J Biol Chem, 279, 401-406. 
Ye, Q., Callebaut, I., Pezhman, A., Courvalin, J.C. and Worman, H.J. (1997) Domain-
specific interactions of human HP1-type chromodomain proteins and inner 
nuclear membrane protein LBR. J Biol Chem, 272, 14983-14989. 
Young, J.I. and Zoghbi, H.Y. (2004) X-chromosome inactivation patterns are 
unbalanced and affect the phenotypic outcome in a mouse model of rett 
syndrome. Am J Hum Genet, 74, 511-520. 
Yusufzai, T.M. and Wolffe, A.P. (2000) Functional consequences of Rett syndrome 
mutations on human MeCP2. Nucleic Acids Res, 28, 4172-4179. 
Zhang, C.L., McKinsey, T.A. and Olson, E.N. (2002) Association of class II histone 
deacetylases with heterochromatin protein 1: potential role for histone 
methylation in control of muscle differentiation. Mol Cell Biol, 22, 7302-7312. 
Zhao, T., Heyduk, T., Allis, C.D. and Eissenberg, J.C. (2000) Heterochromatin protein 1 
binds to nucleosomes and DNA in vitro. J Biol Chem, 275, 28332-28338. 
 
 
ANNEX 
 
-99- 
7. ANNEX 
7.1. Abbreviations 
5mC  5-methyl cytosine 
Brm  Brahma 
CBX  chromobox homolog 
CD  chromodomain 
CDKL5 cyclin dependent kinase like 5 
CoREST co repressor of repressor element RE-1 silencing transcription factor 
CSD  chromoshadow domain 
Dnmt   DNA methyl transferase 
FBP11 formin binding protein 11  
FRAP  Fluorescence recovery after photobleaching  
HAT  histone acetyl transferase 
HDAC  histone deacetylases 
HMGB1 high mobility group protein 1 
HMT  histone methyl transferase 
HP1  heterochromatin protein 1 
LANA  latency associated nuclear antigen  
MeCP2  Methyl CpG binding protein 2 
MBD1  methyl CpG binding protein 1 
MBD  methyl CpG binding domain 
N6mA  N6-methyladenine 
NLS  nuclear localization signal 
NMR  nuclear magnetic resonance 
NuRD  nucleosome remodeling and histone deacetylation 
PAC  P1-derived artificial chromosome 
PU.1  Ets family transcription factor  
RTT  Rett syndrome 
SAM  S-adenosyl-L-methionine 
SET domain  Su(var)3-9, Enhancer of Zeste, Trithorax domain 
TFIIB  transcription factor II B 
TRD  transcription repression domain 
UTR  untranslated region 
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XCI  X chromosome inactivation 
YB1  Y box binding protein 1 
 
Abbreviations listed in the publications are not mentioned here. 
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Abstract
Class II MHC molecules display peptides on the cell surface for the surveillance by CD4+ T cells. To ensure that these ligands
accurately reflect the content of the intracellular MHC loading compartment, a complex processing pathway has evolved
that delivers only stable peptide/MHC complexes to the surface. As additional safeguard, MHC molecules quickly acquire a
‘non-receptive’ state once they have lost their ligand. Here we show now that amino acid side chains of short peptides can
bypass these safety mechanisms by triggering the reversible ligand-exchange. The catalytic activity of dipeptides such as
Tyr-Arg was stereo-specific and could be enhanced by modifications addressing the conserved H-bond network near the P1
pocket of the MHC molecule. It affected both antigen-loading and ligand-release and strictly correlated with reported
anchor preferences of P1, the specific target site for the catalytic side chain of the dipeptide. The effect was evident also in
CD4+ T cell assays, where the allele-selective influence of the dipeptides translated into increased sensitivities of the
antigen-specific immune response. Molecular dynamic calculations support the hypothesis that occupation of P1 prevents
the ‘closure’ of the empty peptide binding site into the non-receptive state. During antigen-processing and -presentation P1
may therefore function as important ‘‘sensor’’ for peptide-load. While it regulates maturation and trafficking of the complex,
on the cell surface, short protein fragments present in blood or lymph could utilize this mechanism to alter the ligand
composition on antigen presenting cells in a catalytic way.
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Introduction
The endosomal route is considered to be the default pathway for
the loading of class II MHC molecules. Here the MHC molecule
encounters internalized proteins serving as antigen source inside
the cell in an acidic lysosomal-like compartment (MIIC) [1,2].
However, experiments with fixed cells or MHC expressing cells
lacking key components of the processing pathway indicate that
MHC loading can take place also directly on the cell surface. This
applies not only for optimally sized peptides but also for larger
polypeptide chains or even full-length proteins [3–5]. In particular
immature dendritic cells (DC) could utilize this pathway. These
DC contain a large fraction of ‘empty’ class II MHC molecules on
the cell surface, which may allow the direct capturing of antigens
from the extracellular space [6,7].
While for these cells cell-surface processing seems to represent a
major antigen-loading pathway, on other cells it could cause
irregular immune responses. Namely on mature DC or activated B
cells the ligands presented on the cell surface should accurately
reflect the peptide composition inside the MIIC compartment.
Presumably as safeguard, a mechanism has evolved that prevents
the ‘accidental’ loading of class II MHC molecules. MHC
molecules, once they have lost their ligand, rapidly convert into
a stable inactive state that is ‘non-receptive’ for free peptides [8,9].
Neither the receptive nor the non-receptive conformation has been
structurally defined yet, so that they are characterized solely by
their kinetic parameters.
While in principle the conversion between the two forms is
reversible, the equilibrium is largely shifted towards the non-
receptive conformation. As a consequence, cell surface loading is
usually very inefficient, which hinders the induction of productive
immune responses during peptide vaccinations. In the endosomal
processing pathway MHC-loading is facilitated by HLA-DM, a
chaperone stabilizing the ‘peptide receptive’ state [10,11]. In
previous studies we have shown that surprisingly also small organic
compounds can exhibit this effect [12,13]. Similarly to HLA-DM,
these ‘MHC-loading enhancers’ (MLE) stabilize a peptide
receptive state resulting in accelerated antigen-loading and ligand
exchange. Here we demonstrate that not only simple organic
chemicals but also amino acid side chains can mediate this effect.
In experiments with short dipeptides we could demonstrate that
they can provoke both ligand exchange and peptide loading when
targeted to the conserved P1 anchor pocket of the class II MHC
molecule. The presence of ‘peptide-MLE’ during T cell assays
therefore significantly improved the cell surface loading of antigen
presenting cells (APC) with peptide antigens, which directly
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translated into an increased sensitivity of antigen-specific T cell
responses.
Results
Studies with synthetic organic MHC ligand-exchange catalysts
pointed already to the P1-pocket as specific target site for ‘MHC-
loading enhancer’ (MLE) [12]. The pocket is located in the
binding groove close to the N-terminal side of the peptide ligand.
In the ligand-complex the pocket accommodates the side chain of
a key anchor residue of the peptide (Fig. 1A). It was therefore
assumed that the MLE-effect may also be achieved with small
natural-like compounds consisting of amino acids. In order to test
this assumption soluble HLA-DR1 molecules were incubated with
the high-affinity peptide ligand HA306-318 in the presence of
amino acids or very short peptides. While free amino acids did not
exhibit any effect (data not shown) the simple dipeptide Tyr-Arg
(YR) accelerated the MHC-loading with the HA306-318 peptide
in a dose-dependent way (Fig. 1B). No effect was observed with the
Ala-Arg (AR) dipeptide lacking the aromatic anchor side chain,
indicating that the replacement of tyrosine by alanine completely
abrogated the MLE-effect.
As illustrated in Fig. 1A the stability of the MHC/ligand
complex is maintained by an H-bond network formed with the
backbone of the peptide. A considerable number of these bonds is
formed in the immediate vicinity of the P1-pocket. To further
stabilize the dipeptide by maximizing the number of H-bonds,
acetyl- and amide-groups were introduced to the N- and C-termini
of the dipeptides. Computational docking of acetylated dipeptide
amide Ac-YR-NH2 to the P1-pocket of HLA-DR1 indicates that
as much as five of the conserved H-bonds can be formed with this
minimal peptide (coordinates of the docking is enclosed in the
supplemental PDB-file PDB_Coordinates S1). Compared to the
free dipeptide YR a more than 10 fold increase in the catalytic
activity was observed with Ac-YR-NH2 (Fig. 2A). A partial MLE-
effect was observed also with Ac-YR and YR-NH2, whereas Ac-
AR-NH2 was still completely inactive. To confirm the importance
of a natural peptide structure, a dipeptide analogue to Ac-YR-
NH2 was employed in which tyrosine was replaced by b-
homotyrosine (b3hY). The introduction of this amino acid
increased the distance between the side chains by an additional
CH2-group and resulted in a total loss of activity (Fig. 2B).
Likewise any replacement of the standard L-amino acids by the
respective D-enantiomer abrogated the catalytic activity. Also the
dipeptide Ac-ry-NH2 composed of D-amino acids in inverse
sequence did not show any effect, indicating a strict stereo-
specificity of the catalyst (Fig. 2C).
Steric requirements, H-bond usage and in particular the failure
of dipeptides lacking the aromatic side chain further supported the
assumption that the effect was mediated by the dimorphic P1
pocket. The pocket of HLA-DR1 (DRB1*0101) contains the
residue b86G, which results in a preference for aromatic and, to a
lower extent, for aliphatic anchor residues [14]. To determine
whether these preferences are reflected in the catalytic activity of
peptide-MLE, a collection of acetylated dipeptide amides was
tested in which the tyrosine residue of Ac-YR-NH2 was replaced
by one of the two other aromatic amino acids phenylalanine (F)
and tryptophan (W) and by the aliphatic amino acids leucine (L),
methionine (M), isoleucine (I), and valine (V). In line with
expectation, strongest increase was observed with the dipeptides
containing F, Y or W, while the dipeptides with aliphatic side
chains showed weaker activity (Fig. 2D). No enhancement was
detected with Ac-ER-NH2 where tyrosine was substituted by
glutamate (E) which belongs to the residues not fitting in the P1
pocket of HLA-DR1 [15].
The mean catalytic MLE-activity is summarized in Table 1. For
soluble HLA-DR1 (DRB1*0101) the catalytic rate enhancement
coefficient was determined to be 6.5 mM21, 3.7 mM21 and
3.5 mM21, for minimal peptide-MLE containing F, Y and W
Figure 1. Amino acid side chains of short peptide fragments can catalyze the formation of MHC/ligand complexes. a) Location of P1
and the H-bond network in class II MHC molecules. Left panel: top view on the peptide binding site of the class II MHC molecule HLA-DR1. Only the
a1- (blue ribbon) and the b1-domain of the MHC molecule (red ribbon) are depicted; position of P1 is indicated. The backbone of the peptide ligand
HA306-318 and the anchor side chain filling the P1 pocket are shown in yellow; MHC residues forming H-bonds with the backbone are labelled in
grey. Right panel: side view of a P1 pocket loaded with the tyrosine anchor side chain. Surface of the pocket is indicated in yellow; amino acid
residues forming this pocket are indicated; the peptide is shown in spacefill mode (green). Images are based on the crystal structure of HA306-318/
HLA-DR1 (PDB: 1DLH) [38]. b) The catalytic impact of dipeptide side chains on the formation of antigen-complexes. The influence of short peptides on
the complex formation-rate between HA306-318 and soluble HLA-DR1 was determined. The loading reaction was carried out in the presence of
titrated amounts of the dipeptides Tyr-Arg (YR, filled circle) or Ala-Arg (AR, open circle) or in the absence of these dipeptides (dashed line). Complex
formation was determined by ELISA and is expressed as relative enhancement in reference to the spontaneous complex formation in the absence of
any catalyst. The amount of catalytic peptide fragments (MLE concentration) is indicated on the x-axis.
doi:10.1371/journal.pone.0001814.g001
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respectively. Compared to Ac-FR-NH2, the dipeptides with
aliphatic MLE side chains exhibited only between 12% (L) and
4% (V) of the activity. Similar catalytic activity was also detected
for some unmodified tripeptides as well as for two peptides derived
from invariant chain (LRMK, LRMKLPK) [16]. As ‘Ii-key’ they
had been described to facilitate MHC-loading by targeting an
allosteric invariant chain binding site located outside the P1
pocket. Their activity, however, was not significantly higher than
that of the unmodified tripeptides and the combined use with the
more active peptide-MLE Ac-FR-NH2 did not show any
cooperativity (data not shown). Notably, no effect was observed
for the N-terminal fragment of the invariant chain octapeptide
(LRKPPKPV). Although the fragment was reported to facilitate
antigen-loading and catalyze the self-release of the invariant chain
peptide IC106-120 (CLIP) [17] at least in this experimental system
no catalytic effect was observed.
So far, the impact of peptide-MLE was determined only on the
loading of empty MHC molecules. To evaluate their influence on
complex dissociation soluble class II MHC molecules were
preloaded with the medium affine CLIP peptide (Fig. 3). Although
the peptide binds to HLA-DR1 with lower affinity than HA306-
318 there was virtually no spontaneous decay detectable (left
Figure 2. Structure/activity relationships of catalytic dipeptides. a) Role of H-bonds for the catalytic activity of dipeptides. Various H-bond
bridges proximal to the P1 pocket stabilize the ligand complex (compare Fig. 1a). N-terminal acetylation and C-terminal amidation was introduced to
the YR dipeptide to facilitate the utilization of this H-bond network by minimal peptide-MLE catalysts. The influence was demonstrated in loading
reactions with HA306-318 and sol. HLA-DR1 in the presence of titrated amounts of YR (filled circle), Ac-YR (open circle), YR-NH2 (open triangle), Ac-YR-
NH2 (open square) and as control Ac-AR-NH2 (open diamond). b) Impact of elongated side chain spacing. A dipeptide derivative was used in which
the side chain spacing was elongated a single CH2-group by using the L-b-homotyrosine (Ac-b3hYR-NH2; open circle) instead of tyrosine (Ac-YR-NH2;
filled circle). c) Influence of D-amino acids. Complex formation was carried out in the presence of titrated amounts of Ac-YR-NH2 (filled circle), Ac-ry-
NH2 (open circle), Ac-rY-NH2 (open triangle), Ac-Ry-NH2 (open square), Ac-yR-NH2 (open diamond), Ac-Yr-NH2 (open triangle up), Ac-yr-NH2 (open
hexagon). D-amino acids are indicated by small letters. d) Structural requirements of the catalytic anchor side chain. The P1 pocket of HLA-DR1
interacts preferably with bulky hydrophobic anchor side chains. To compare the catalytic activity with the known structural preferences of P1 the
complex formation of HA306-318/HLA-DR1 is shown for Ac-FR-NH2 (filled circle), Ac-WR-NH2 (filled triangle down), Ac-YR-NH2 (filled square), Ac-LR-
NH2 (open circle), Ac-MR-NH2 (open triangle down), Ac-IR-NH2 (open square), Ac-VR-NH2 (open diamond), Ac-ER-NH2 (open triangle up).
doi:10.1371/journal.pone.0001814.g002
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panel). The same applies also when the experiment was carried out
in the presence of dipeptide-MLE. The situation looked different
when HA306-318 peptide was added (right panel). In less than
2 h, 50% of the HLA-DR1/CLIP complex disappeared when Ac-
FR-NH2 was present during dissociation. Notably, in the absence
of catalyst more than 80% of the complex still remained intact
even after 64 h of incubation indicating that the dipeptide-MLE is
able to increase also the off-rate of peptide-ligands. In the presence
of Ac-YR-NH2 and Ac-LR-NH2 the half-life was shortened to
,4 h and,10 h while Ac-AR-NH2 had only a very limited effect.
The reversible acceleration of both complex formation and
complex dissociation could therefore be correlated with the
anchor preference of the P1 pocket.
In order to formally demonstrate that the catalytic side chains of
peptide-MLE act through the P1 pocket, mutants of HLA-DR1 were
generated in which the glycine residue b86 at the floor of P1 was
replaced either by valine (b86V) or by tyrosine (ß86Y) (Fig. 4). In
HLA-DR, b86V represents the natural dimorphic alternate to
b86G. Occupation of b86 by valine produces a shallow hydrophobic
pocket that is able to accommodate aliphatic side chains but, in
contrast to b86G-pockets, is too small for bulky aromatic residues
[18]. The non-natural substitution b86Y has been shown to produce
MHC molecules that are highly receptive but contain a P1 pocket
blocked by the tyrosine residue [19]. Here, only those peptides can
bind where the binding does not depend on the P1 pocket.
Therefore, loading experiments were therefore carried out with
ABL908-922, a pentadecapeptide derived from the ABL kinase that
can form a complex with all three variants (Ho¨pner et al. manuscript
in preparation) (Fig. 4, upper panels). In the absence of any peptide-
MLE, ABL908-922 binds equally strong to wt HLA-DR1 (b86G)
and HLA-DR1 (b86GRV). Due to the inherently increased
receptiveness of the mutant [19], it exhibits the highest spontaneous
on-rate with HLA-DR1 (b86GRY). Also here the addition of
peptide-MLE resulted in increased loading reactions (Fig. 4, lower
panel). With wt HLA-DR1 (b86G) the enhancement of ABL908-922
loading corresponded to the result obtained with HA306-318, in
which the aromatic dipeptides showed stronger enhancements than
the aliphatic Ac-LR-NH2 peptide. The pattern was reversed for
HLA-DR1 (b86GRV). In line with the anchor preferences of the
shallow P1 pocket, best enhancement was obtained with Ac-LR-
Table 1. Catalytic activity of short peptides on the loading of
soluble HLA-DR1 with HA306-318
Compound*
Catalytic Rate Enhancement**
[6103 M-1 ]
rel. cat.
Activity*** [%]
a) Minimal peptide-MLE
1 Ac-FR-NH2 6.5 +/2 1.2 100
2 Ac-YR-NH2 3.7 +/2 1.0 57
3 Ac-WR-NH2 3.5 +/2 0.9 54
4 Ac-LR-NH2 0.76 +/2 0.08 12
5 Ac-MR-NH2 0.52 +/2 0.00 8
6 Ac-IR-NH2 0.43 +/2 0.01 7
7 Ac-VR-NH2 0.25 +/2 0.02 4
8 Ac-ER-NH2 0.02 +/2 0.02 0
9 Ac-AR-NH2 0.00 +/2 0.00 0
b) Catalytic tripeptides
10 YFR 0.68 +/2 0.29 11
11 YKT 0.59 +/2 0.12 9
12 KYV 0.51 +/2 0.15 8
13 GYV 0.49 +/2 0.16 8
c) ‘Invariant Chain’-derived peptides
14 LRMKLPK 0.98 +/2 0.21 15
15 LRMK 0.53 +/2 0.15 8
16 LRKPPKPV 0.00 +/2 0.00 0
*‘Minimal peptide-MLE’ and ‘catalytic tripeptides’ are introduced in this study,
catalytic activity for ‘invariant chain derived peptides’ has been reported for
LRMK and LRMKLPK [16] and for LRKPPKPV [17].
**The ‘Catalytic Rate Enhancement’ coefficient (k) represents the relative
increase of the spontaneous loading rate (rspont) in the presence of the
catalytic peptide (Pcat). The total rate (rtot) can be calculated by (rtot = rspont+
k [Pcat] rspont).
***‘‘rel. cat. Activity’’ indicates the relative catalytic activity of peptide derivatives
and is expressed as percentage in reference to the catalytic rate
enhancement of Ac-FR-NH2.
doi:10.1371/journal.pone.0001814.t001
Figure 3. Catalytic dipeptides trigger reversible ligand exchange. To demonstrate that peptide-MLE can catalyze the reversible ligand
exchange, complex dissociation of CLIP/HLA-DR1 induced by the peptide-MLE was determined in the absence (left panel) or presence of 200 mg/ml
free HA306-318 (right panel). In this experiment 10 mM Ac-FR-NH2, (filled circle), Ac-YR-NH2 (filled triangle), Ac-LR-NH2 (open circle), Ac-AR-NH2 (open
triangle) or no catalysts (cross) was used. The percentage of CLIP/HLA-DR1 complex remaining after indicated time points was determined by ELISA.
doi:10.1371/journal.pone.0001814.g003
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NH2 while weaker amplification was detected with aromatic
dipeptides. No enhancement was observed with HLA-DR1
(b86GRY). Even a slight reduction was detected at the highest
dipeptide concentration used, while 4-chlorophenol (pCP), a simple
disubstituted benzene known to act independent of P1 [12,13], still
exhibited an MLE-effect.
Exposure of cells to synthetic organic MLE facilitated the antigen
loading directly on cell surface MHC molecules [12,13]. To
determine whether this applies also for peptide-MLE, 721.221 cells
expressing HLA-DR1-GFP fusion proteins (721.221-DRb1GFP)
were incubated in the absence or presence of Ac-FR-NH2 with
biotinylated HA306-318 peptide. After staining with fluorescence-
labelled streptavidin, imaging of the cells by confocal laser scanning
microscopy revealed a striking increase in the amount of peptide
bound to the cell surface in the presence of Ac-FR-NH2 (Fig. 5A).
While almost no HA306-318 peptide was detectable when the
loading was carried out in the absence of the dipeptide-MLE, the
addition of the catalyst resulted in a bright surface staining that
colocalized with the HLA-DR1-GFP fusion protein.
In a more detailed analysis the peptide loading of cells was
analyzed by FACS (Fig. 5B). For these experiments fibroblast cells
were used that do not express endogenous class II MHC molecules
but were transfected with full length versions of wt HLA-DR1
(b86G) and mutated HLA-DR1 (b86GRV). As in the previous
experiment the cells were incubated with biotinylated MHC-
binding peptide ABL908-922 in the absence or presence of titrated
amounts of catalytic dipeptides (Fig. 5B, upper panels). Quanti-
fication of peptide-loading by FACS revealed a similar pattern as
observed before with soluble MHC molecules (compare Fig. 4).
On fibroblasts expressing wt HLA-DR1 the strongest enhance-
ment was observed with aromatic dipeptides, while the aliphatic
Ac-LR-NH2 peptide showed the weakest effect. Similar effects
were also observed with bone-marrow derived dendritic cells
obtained from HLA-DR1 transgenic mice (data not shown). On
cells expressing the mutated b86GRV molecule, the aliphatic Ac-
LR-NH2 was more effective than the peptide-MLE with aromatic
side chains. Thus, also the enhancement cell surface loading
correlated with the allele-specific anchor preferences of P1.
Importantly, the increased loading efficiency translated directly
into improved CD4+ T cell responses (Fig. 5B, lower panels).
CD4+ T cell hybridoma specific for the ABL epitope (SaABL/G2)
showed the strongest response when they were stimulated with
fibroblast cells that had been loaded before in the presence of the
dipeptides. The pattern of enhancement reflected the catalytic
Figure 4. Allele selectivity of catalytic dipeptides. Recombinant soluble HLA-DR1 molecules were mutated inside the P1 pocket and used in
loading experiments with ABL908-922, a peptide able to bind to wt as well as to the mutated forms of HLA-DR1 (S. Ho¨pner, unpublished). Upper
panels: the spontaneous loading of ABL908-922 is shown for wt HLA-DR1 (b86G), for HLA-DR1 (b86GRV) and HLA-DR1 (b86GRY). The formation of
ABL908-922/HLA-DR complex is expressed in counts per minute (cpm); dashed line indicates background signal. Lower panels: The allele-selective
effect of catalytic dipeptides is shown. The influence on HLA-DR loading is shown for Ac-FR-NH2 (filled circle), Ac-WR-NH2 (filled triangle down), Ac-
YR-NH2 (filled square) and Ac-LR-NH2 (open circle) and for p-chlorophenol (pCP; cross with dashed line), a simple aromatic MLE compound acting
independent of P1 [13]. 1.5 mg/ml ABL908-922 were used for wt HLA-DR1 and HLA-DR1 (b86GRV) and 0.2 mg/ml for HLA-DR1 (b86GRY). Complex
formation is expressed as relative enhancement in reference to the spontaneous complex formation in the absence of any catalyst. The loading was
determined by ELISA.
doi:10.1371/journal.pone.0001814.g004
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effect on antigen loading as it directly correlated with the allele-
specific P1-anchor preference. Aromatic dipeptides were most
efficient on wt HLA-DR1 (b86G) while the aliphatic Ac-LR-NH2
showed best stimulation with cells expressing the mutated HLA-
DR1 (b86GRV) with the shallow P1 pocket.
The influence of catalytic dipeptides on the CD4+ T cell
response was further studied in in vitro T cell assays in which T cells
and APC were exposed to free peptide antigens and peptide-MLE.
In these experiments HA306-318 was used as antigen to challenge
two different HLA-DR-restricted CD4+ T cells, the mouse T cell
hybridoma EvHA/X5 (Fig. 6A, upper panels) and the human T
cell line PD2 (Fig. 6A, lower panels). For both cell lines the
presence of peptide-MLE resulted in a drastic increase in the
sensitivity of the T cell response. Titration of the peptide-MLE at
suboptimal antigen dosage revealed maximal enhancement of the
T cell response at concentrations around 2–3 mM (left panels). At
these concentrations the dose response curves for the HA306-318
antigen were shifted up to 50-fold towards lower concentrations
(right panels). While a half-maximal response in the absence of
catalyst was detected at a concentration of 31 ng/ml for EvHA/
X5 and of 14 ng/ml for PD2, Ac-FR-NH2 lowered the threshold
to 0.65 ng/ml and 0.23 ng/ml, respectively. In line with the
previous data weaker effects were determined with Ac-LR-NH2.
Lastly, to confirm that peptide-MLE mediated enhancement
can be observed also with primary cells, lymph node cells from
HLA-DR1tg mice were challenged ex vivo in the absence or
presence of Ac-FR-NH2. The mice were primed either with
HA306-318 or with NY-ESO-1 89-101, a CD4+ T cell epitope
derived from the NY-ESO-1 protein associated with various solid
tumours [20]. After 12 days the antigen-specific ex vivo response
was determined by an IFN-c ELISPOT assay (Fig. 6B). In line
with the previous results, the catalytic dipeptide was found to
significantly increase the sensitivity of the assay. At concentrations
of 5 ng/ml HA306-318 (upper panel) and of 50 ng/ml NY-ESO-1
89-101 (lower panel) the number of spots representing single IFN-c
secreting cells was significantly higher when the Ac-FR-NH2 was
added. Thus, short peptides exhibiting MLE-like activity can
amplify immune responses also in primary cultures containing
‘natural’ CD4+ T cells and professional APC.
Discussion
Our experimental data show that short peptide fragments can
influence the ligand composition of class II MHC molecules in a
catalytic way. By placing an amino acid side chain into a defined
pocket of the MHC molecule they trigger ligand-exchange and
antigen-loading. Mutational analysis indicated already that the
occupation of pocket P1 is crucial for the catalytic effect of organic
MLE compounds [12]. As demonstrated here for the human
molecule HLA-DR1, a similar role could also be established for the
ligand exchange driven by short peptides. P1 is present in all MHC
class II molecules. It is located within the peptide binding site and
accommodates the side chain of a key-anchor residue of the peptide
ligand. While the location of the pocket is conserved, it contains
polymorphic residues that determine allele-specific preferences for
anchor residues. Since the same structural requirements also dictate
the interaction with ‘catalytic’ side chains of short peptides, they
exhibit their effect in an allele-selective way.
As shown before for simple organic compounds the MLE
mechanism is based on the stabilization of the peptide-receptive
Figure 5. Enhanced loading of cell surface MHC by peptide-MLE. a) Confocal laser scanning analysis of cell surface loading. 721.221-DRb1GFP
cells expressing a GFP-tagged HLA-DR1 molecule were incubated with biotinylated HA306-318 peptide in the absence or presence of Ac-FR-NH2.
After staining with streptavidin-Cy5 images were taken by confocal laser scanning microscopy. Scale bar represents 10 mm. b) Impact on APC loading
and T cell response. Fibroblast transfectants expressing either wt HLA-DR1 (left panels) or mutated HLA-DR1 (b86GRV; right panels) were incubated
with ABL908-922 in the presence of titrated amounts of Ac-FR-NH2 (filled circle), Ac-WR-NH2 (filled triangle), Ac-YR-NH2 (filled square), Ac-LR-NH2
(open circle) or in the absence of any peptide-MLE. Upper panels: Analysis of cell surface loading by FACS. Fibroblast cells were incubated with 12 mg/
ml biotinylated ABL908-922. After 4h peptide loading was determined by FACS and is expressed as geometrical mean (geo. mean). Lower panels:
Enhancement of the ABL908-922-specific T cell response. Fibroblast cells expressing wt HLA-DR1 or HLA-DR1 (b86GRV) were incubated for 4 h with
150 ng/ml or 300 ng/ml ABL908-922, washed and used to challenge SaABL1/G2, an ABL908-922 specific T cell hybridoma that recognizes the peptide
on both HLA-DR1 molecules. The response is expressed as IL-2 release; dashed lines represent the T cell response triggered in the absence of any MLE
compounds.
doi:10.1371/journal.pone.0001814.g005
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conformation [12]. Earlier studies showed already that the
substitution of residue b86G by tyrosine resulted in a ‘filled’ P1
pocket and produced an MHC molecule with elevated receptive-
ness [21]. P1 is located proximal to the binding site of HLA-DM
and binding studies suggested that HLA-DM interacts specifically
with the flexible empty hydrophobic P1-pocket [21]. While the
active conversion of a non-receptive molecule by HLA-DM has
recently been questioned [22], it is undisputed that the chaperone
interacts with a region proximal to P1 to stabilize the peptide
receptive conformation [10,11,23,24].
In a recent publication we introduced a model in which the
transition to the non-receptive state is directly correlated with
structural changes inside pocket P1. Experimental evidence was
taken from the observation that P1-targeting MLE compounds
prevent this transition [12]. The strict correlation of the catalytic
activity with the structural requirements of P1 introduced by this
study provides additional support to the hypothesis that the
stabilization of P1 prevents the transition into the non-receptive
state. A molecular dynamic (MD) simulation confirmed that the
pocket P1 is indeed quickly lost when the peptide ligand is stripped
off from the MHC molecule (Rupp et al. manuscript in
preparation) (Fig. 7). Calculations based on the coordinates of
the crystal structure of the HLA-DR1/HA306-318 complex
revealed that the most significant transitions were detected near
the P1 pocket. While these shifts resulted in a narrowing of the two
a-helices by more than 7A˚ (Fig. 7A), they also led to a complete
loss of the P1 pocket. In less than 15 ns the P1 cavity was filled
with side chains or removed by distortions (Fig. 7C,D). Notably,
this collapse was prevented when prior to the MD simulation the
Ac-FR-NH2 was docked into the P1 pocket (Fig. 7B).
Based on this model even the partial occupation of the binding site
by a very short peptide is sufficient to stabilize the receptive state as
long as it positions an anchor side chain inside the P1-pocket
(supplemental PDB file PDB_Coordinates S1). P1 therefore seems to
function as a sensor for the peptide load where occupation leads to a
stabilization of the ‘open’ conformation required to accommodate
the peptide ligand. Studies by other groups have already shown that
the loading status of P1 plays a crucial role as indicator in the
intracellular antigen-processing pathway. The interaction with
HLA-DM seems to depend on the loading state [21] and its catalytic
activity was reported to be mediated by bH81, a conserved residue
located on top of the P1 pocket [24].
While inside the cell the occupational state of P1 seems to
control the interaction with key-components of the processing
pathway, on the cell surface it may regulate the transition into the
non-receptive conformation. Here, it functions as trigger for a
safeguard mechanism that closes the binding site as soon as the
ligand is lost. In this study we showed that small peptide fragments
can by-pass this mechanism in a catalytic way. Particularly striking
is the effect on the ligand exchange. Peptide-MLE were able to
increase not only the loading of empty HLA-DR molecules but
also the dissociation of HLA-DR molecules preloaded with lower-
Figure 6. Amplification of the antigen-specific T cell response. a) Enhancement of the in vitro T cell response. The influence of catalytic peptides
on the antigen-specific CD4+ T cell response was tested with a mouse T cell hybridoma EvHA/X5 (upper panels) and a human T cell line PD2 (lower
panels). Both recognize the HA306-318 antigen in the context of HLA-DR1. The left panels show the influence of titrated amounts of Ac-FR-NH2 (filled
circle), Ac-YR-NH2 (filled triangle) or Ac-LR-NH2 (open circle) by EvHA/X5 and PD2 in the presence of 15 or 2 ng/ml HA306-318, respectively. The response
in the absence any catalyst is indicated as a dashed line. The right panels are showing the dose response curves of HA306-318 in the presence of 5 mMAc-
FR-NH2 (filled circle) or Ac-LR-NH2 (open circle), 3 mM Ac-YR-NH2 (filled triangle) or in the absence of any peptide-MLE (cross). Dashed line indicates the
background. b) Enhancement of the ex vivo T cell response. Lymph node cells were isolated fromHLA-DR1tg mice primed with HA306-318 peptide or NY-
ESO-1 89-101. The ex vivo response was determined by an IFN-c ELISPOT assay by challenging the cells with 5 ng/ml HA306-318 (upper panel) or 50 ng/ml
NY-ESO-1 89-101 (lower panel), respectively. The bars represent the number of spots detected in the absence (black bar) or presence of 2.5 mMAc-FR-NH2
(grey bar). Each spot originates from a single IFN-c secreting cell; dashed line indicates the background signal.
doi:10.1371/journal.pone.0001814.g006
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affinity ligands in a reversible reaction. Both effects should account
for the increased antigen-loading of cell surface MHC molecules,
which translated directly into improved CD4+ T cell responses. As
molecular tool MLE compounds may therefore find applications in
experimental and therapeutic settings in which improved antigen
loading is desired. A particular suitable field may be peptide-based
tumour immune interventions, where the exposure of antigen to a
hostile proteolytic environment is extended by the limited access to
receptive MHC molecules on the surface of professional APC.
While the importance of CD4+ T cells for productive tumour
immune responses has just begun to be fully discovered [25] their
role in the induction of autoimmune responses has long been
acknowledged [26]. It is evident for instance in the strong genetic
link to class II MHC molecules and in the fact that experimental
autoimmune diseases can often be induced by the adoptive
transfer of auto-aggressive CD4+ T cells. In this respect
‘accidental’ loading of these cells with self-antigens by peptide-
MLE may therefore trigger unwanted auto-aggressive responses.
In vitro we have shown already that the presence of simple organic
MLE compounds can enhance encephalitogenic T cell responses
[12,13]. The same may also apply for colitis or celiac disease.
Intestinal dendritic cells are known to penetrate gut epithelia cells
[27] and expose their dendrites inside the gut lumen to extremely
high polypeptide concentrations originating from the diet or
commensal debris. Capture of soluble antigens by immature DC
from lymph or blood, on the other hand, also seems to be an
important mechanism for tolerance induction [28] and direct cell
surface loading has been discussed as an alternative processing
pathway of immature dendritic cells [6,7]. Natural protein
fragments present in blood or lymph acting as peptide-MLE
may therefore participate in this process by mediating the direct
transfer of antigens onto cell surface MHC molecules.
Materials and Methods
Compounds and reagents
The following peptides were used: IC106-120 (KMRMATPL-
LMQALPM; ‘CLIP’ peptide) [29], HA306-318 (PKYVKQNT-
LKLAT) [30], NY-ESO-1 89-101 (EFYLAMPFATPME) [20] and
human ABL 908-922 (KGKLSRLKPAPPPPP) (Hopner et al.,
Figure 7. Molecular dynamic (MD) calculation of ‘empty’ and peptide-MLE stabilized HLA-DR1. The coordinates of the MHC component
of the crystallized HLA-DR1/HA306-318 complex (1DHL) were used to carry out a 15 ns MD calculation with an ‘empty’ MHC molecule. a) Dynamic of
the empty MHC molecule. The floor composed of the b-plated sheats is depicted in magenta, the a-helices of the starting structure are shown in red,
a-helices of the structure obtained after 15 ns are shown in blue. The approximate position of P1 is indicated. While the dynamic was carried out with
all extracellular domains, only the binding site is shown (a1-, b1-domain). b) Dynamic of the peptide-MLE stabilized MHC molecule. The same MD
calculation was carried out as in Fig. 7a except that coordinates of an HLA-DR1 molecule were used, in which prior to the MD calculation the peptide-
MLE Ac-FR-NH2 was docked into the P1 pocket. c) P1 pocket in the peptide loaded MHC complex. The image shows a cross-section of the HLA-DR1/
HA306-318 complex. The surface of the MHC molecule is shown in yellow, the peptide ligand in red; position of the P1 pocket is indicated. d) Loss of
P1 in the empty MHC molecule. The same cross-section shown in Fig. 7c for the peptide-loaded MHC is shown here for the empty molecule obtained
after 15 ns of MD calculation. In this structure the P1 pocket can no longer be located.
doi:10.1371/journal.pone.0001814.g007
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unpublished). N-terminal biotinylation was introduced using two
6-amino hexanoic acid spacer units. Stock solutions of short
peptides (100 mM) were prepared with DMSO/PBS after
ultrasound sonication at the following DMSO concentrations:
YR, AR (0%); LRMK, YFR, GYV, Ac-AR-NH2, Ac-ry-NH2, Ac-
rY-NH2, Ac-Ry-NH2, Ac-yR-NH2, Ac-Yr-NH2 and Ac-b3hYR-
NH2 (10%); Ac-FR-NH2, Ac-YR-NH2, Ac-LR-NH2, Ac-ER-NH2
(15%); LPKPPKPV (20%); Ac-WR-NH2 (25%); Ac-VR-NH2, Ac-
MR-NH2, Ac-IR-NH2, Ac-RY-NH2 (100%). All peptides were
produced by EMC microcollections GmbH (Tu¨bingen, Germany)
and analyzed by RP-HPLC (214 nm) and ESI-MS.
Antibodies and soluble HLA-DR1
Phycoerythrin- (PE) conjugated streptavidin was purchased from
Caltag, a-HLA-DR-PE (L243) was obtained from BD Biosciences.
Unlabelled a-HLA-DR (L243) and a-IFN-c (AN18.1724 and R4-
6A2) were purified from hybridoma supernatant by Prot.A and
Prot.G columns (GE Healthcare). R4-6A2 was labeled with NHS-
Biotin according to the manufactures recommendation (Pierce).
Soluble wt HLA-DR1 (DRA*0101, DRB1*0101) [31] was produced
in S2 insect cells as described [13]. Mutant forms of HLA-DR1 were
expressed in a baculovirus expression system. Briefly, DNA coding
for the extracellular domains of DRA*0101 and DR1B*0101 was
separately cloned into the transfer vector pFastbac 1 (Invitrogen).
Leucine zipper domains were added to the C-termini of the a- and b-
chain as described [32]. Site-directed mutagenesis of HLA-DR1 b-
chain was carried out using the QuickChange site-directed
mutagenesis kit (Stratagene). Recombinant viruses were generated
in S. frugiperda cells (Sf21). For expression of proteins, cells were co-
infected with viruses for the a- and b-chain.
Cells
The following class II expressing cell lines were used: L929
fibroblasts (ATCC) transfected with wt (DRB1*0101) or mutated
HLA-DR1 (HLA-DRB1*0101 b86V) [12], EBV-transformed B
cell 721.221 (ATCC) and HTR [33]. 721.221-DRb1GFP cells
were produced by stably transfecting 721.221 cells with a HLA-
DR ß-chain (DRB1*0101) C-terminally fused to EGFP (Falk et al.
unpublished). The following T cells were used: DRB1*0101-
restricted, HA306-318-specific mouse hybridoma line EvHA/X5
[12] and human CD4+ T cell line PD2 [33]; the ABL 908-922-
specific T cell hybridoma SaABL/G2 was generated after fusing a
CD4+ T cell line generated in HLA-DR1 tg mice [34] with BW
cells (Hopner et al., unpublished).
Peptide loading of soluble HLA-DR1 molecules
Loading experiments with soluble MHC molecules were carried
out as described [13]. Briefly, 100 nM HLA-DR1 was incubated
with 50 mg/ml of biotinylated HA306-318 peptide (PBS, pH 7.4,
37uC, 1 h). The amount of peptide/MHC complex formed was
determined by ELISA with the a-HLA-DR capture antibody (L243,
ATCC) and Eu3+-labelled streptavidin (DELFIA,Wallac) using a
Victor 3V reader (Perkin Elmer). Ligand exchange experiments were
carried out with preloaded HLA-DR1/CLIP complexes (1,5 mM
HLA-DR1, 50 mg/ml biotinylated CLIP, 18-20 h, pH 7.4, 5%
ethanol/PBS) diluted 1:15 and incubated with or without 200 mg/ml
HA peptide in presence and absence of 10 mM dipeptide [12]. All
experiments are carried out at 2 or 3 times.
Peptide loading of cell surface MHC molecules
Loading experiments were carried out as described [12]. Briefly,
16105 HLA-DR expressing cells/well were incubated with
biotinylated MHC-binding peptides in presence and absence of
catalytic dipeptides (4 h, 37uC, DMEM, 5% FCS, 96 well V-
bottom plates). For FACS analysis cells were stained with
streptavidin-PE and analyzed on a FACScalibur instrument (BD
Biosciences). Dead cells were excluded by propidium iodide
staining. Experiments were carried out twice.
Confocal laser scanning microscopy
Briefly, 16105 HLA-DR1 expressing cells (721.221-DRb1GFP)
per well were incubated with 20 mg/ml of biotinylated HA 306-
318 peptide in presence and absence of 2.5 mM Ac-FR-NH2 (4 h,
37uC, DMEM, 5% FCS, 96 well V-bottom plates). Cells were then
washed and were incubated on poly-L-lysine (sigma) coated plates
for 30 min. at 37uC in RPMI medium (Gibco), followed by a
15 min. 3.7% formaldehyde fixation. After washing cells were
stained with streptavidin-Cy5 (Amersham) and mounted with
vectashield (vector labs). Fixed cell microscopy was performed with
a Zeiss LSM510Meta confocal setup (636 phase contrast plan-
apochromat oil objective). Experiments were carried out twice.
T cell assays
T cell assays were carried out as described [13]. Briefly, 56104
HLA-DR expressing cells/well were incubated with MHC-binding
peptides in presence and absence of catalytic dipeptides (37uC,
DMEM, 5% FCS, 96 well round-bottom plates). In assays with
antigen-pulsed APC, cells were washed after 4 h before 56104 T
cells were added, in permanent exposure assays the T cells were
added directly without prior removal of the peptides. In experiments
with T cell hybridoma the culture supernatant was removed after
24 h and the T cell response was determined by measuring IL-2
release in a secondary assay with CTLL cells (ATCC) as described
previously [35]. In experiments with T cell lines, APC were radiated
with 60.7 Gy and 3H-thymidine was added after 48h and the
incorporation was determined using a 1450 Microbeta counter
(Wallac). Experiments were carried out twice.
Detection of ex vivo response by ELISPOT assay
HLA-DR1tg mice were primed with 5 mg HA306-318 or 10 mg
NY-ESO-1 89-101 in incomplete Freud’s adjuvant (Sigma)/50 mg
CpG OND 1826 (BioTez GmbH). On day 12, lymph node cells
were isolated and incubated in ELISPOT-plates (Multiscreen HTS
96 well Filteration plate; Millipore) coated with a-IFN-c (clone
AN18.1724). Cells were incubated at a density of 16106
splenocytes/well with indicated amounts of HA306-318 and Ac-
FR-NH2 peptide (20–40 h, 37uC, 5% CO2, RPMI 5% FCS).
Detection was carried out according to manufacturer’s recommen-
dation using the biotinylated a-IFN-c detection antibody (clone R4-
6A2), avidin–HRP enzyme conjugate (Sigma) and 3,3 diaminoben-
zidine tablets (Sigma). Spots were counted using ‘Immunospot’
reader (C.T.L Europe GmbH). Experiments were carried out twice.
Calculation of the ‘catalytic rate enhancement’
The ‘catalytic rate enhancement’ coefficient was determined in
loading assays with 100 nM soluble HLA-DR1 and 50 mg/ml
HA306-318 with titrated amounts of the catalytic peptide-MLE (1 h,
37uC, pH 7.4). A curve fit was carried out by a hyperbola regression
(f(x) = ax/(b+x)) using the Sigmaplot Version 9.0 software (Systat
Software Inc.) and the coefficient was determined by forming the
average of the starting slope (a/b) of 2–4 independent experiments.
Docking and ‘Molecular Dynamics’ calculation
The benzene ring of the phenylalanine residue and the
backbone of the Ac-FR-NH2 dipeptide were superimposed to
the residues Y308 and V309 of the HA306-318 peptide in the
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HA306-318/HLA-DR1 crystal structure 1DLH, followed by a
conformation search with the arginine side chain of the dipeptide
to find an optimal orientation. Subsequently, the complex
structure was minimized using the Tripos software (SYBYL 7.3,
Tripos Inc., St. Louis, USA) and the GROMACS force field [36].
For both, the empty MHC structure and the Ac-FR-NH2/MHC-
complex, a 15 ns molecular dynamic simulation in the GRO-
MACS force field was performed (Rupp et al., manuscript in
preparation). The simulations were done under physiological
conditions (0.9% NaCl, 310 K) after equilibration over a period of
500 ps using a positional restraint of 1000 kJmol21nm22. Frames
were stored every 5 ps, visualisation of trajectories and arrange-
ment of the figures were realised using VMD [37].
Supporting Information
PDB_Coordinates S1 The text file contains the calculated
coordinates of the complex Ac-FR-NH2/HLA-DR1 in PDB-file
format. For the docking of Ac-FR-NH2 the benzene ring of the
phenylalanine residue and the backbone of the dipeptide were
superimposed to the residue Y308 (located within the P1 pocket)
and V309 of the HA306-318 peptide in the HA-306-318/HLA-
DR1 crystal structure 1DLH. Subsequently, the complex was
minimized using Tripos and the GROMACS force field. Chain A:
HLA-DR1 a-chain (DRA*0101); chain B: HLA-DR1 b-chain
(DRB1*0101); chain C: Ac-FR-NH2
Found at: doi:10.1371/journal.pone.0001814.s001 (0.26 MB
TXT)
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